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CHAPTER 1 
1.1.11\iTRODUCTION 
Growth promoting effects of crude anterior pituitary extracts in hypophysectomized 
and intact laboratory animals were first demonstrated in 1921 by Evans and Long (1). 
Following further isolation the diverse physiologic effects of a relative pure growth 
promoting factor in animals were described by Li et al in 1949 (2). After 
demonstration of a species specificity among growth hormones (GH) (3,4,5,6) 
and the development of a new procedure for crystallizing GH, enabling more GH with 
an increased purity to be obtained from human pituitaries (7), Beck et al (8) were 
the first to report the effects of human and monkey growth hormone in man. 
Subsequently many other reports appeared investigating the effects of the 
administration of pituitary- derived primate GH, for 1 week to 6 months, in adults with 
GH deficiency, in patients with a variety of other diseases and in normals 
(9, 10,11, 12). These effects included increased nitrogen, phosphorus, 
potassium and sodium retention, increased calcium absorption, hypercalciuria and 
disturbances in carbohydrate metabolism. 
Effects of GH administration in patients with burns (13,14,15) or trauma (16) 
were also investigated and showed promising results as to the reversal of 
catabolism/induction of anabolism. 
Raben was the first to report the successful stimulation of growth with human GH in 
a child with GH deficiency (17), and this was followed by many other reports 
(reviewed in ref 18). 
Due to the species specificity, requiring GH to be derived from the limited supply of 
primate (human) pituitaries obtained at autopsy, GH remained scarce. Its therapeutic 
use remained, under strict medical supervision by paediatric endocrinologists, limited 
to the treatment of children with dwarfism due to GH deficiency. Even in these children 
GH was administered in regimens now known to be insufficient for optimal growth, 
however. 
In 1985 the use of human pituitary-derived GH had to be stopped completely after 
reports of contamination of batches of GH by one or more pituitaries containing a 
"slow virus" causing Creutzfeldt-Jacob disease and resulting in several deaths 
(19,20,21 ,22,23,24). 
Following the development of recombinant DNA technology several pharmaceutical 
companies developed the ability to produce in limitless quantities human GH in vitro 
by Escherichiae Coli. Since 1986 Humatrope, bioequivalent and identical to human GH, 
manufactured by Eli Lilly & Co (Indianapolis, USA) is available for the treatment of 
children with short stature and research in adults (25). Other pharmaceutical 
industries also producing human GH are Novo Nordisk (Norditropin), KabNitrum 
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(Genotropin) and Genentech (Protropin). 
The studies described in this thesis have all been performed with Humatrop, provided 
for free by Eli Lilly Nederland. 
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1.2. PHYSIOLOGY OF GROWTH HORMONE SECRETION AND ASSESSMENT 
OF GH DEFICIENCY 
Physiology of GH secretion 
Growth hormone is synthesized, stored and secreted by the somatotrophic cells in the 
anterior lobe of the pituitary gland. It is a single-chain peptide of 191 amino acids with 
two intramolecular S-S bounds and without carbohydrate substituents. It has a 
molecular weight of 22 KDa (1). About 10% of the GH in the pituitary is in a smaller 
20 KDa form, due to aberrant processing of GH mRNA precursor. 
Growth hormone is secreted in an intermittent pulsatile fashion (2,3,4) regulated 
by a balance between stimulatory (Growth Hormone Releasing Hormone, GHRH) and 
inhibitory (Somatostatin, SMS) hypothalamic hormones (5), which reach the pituitary 
through the hypophyseal portal circulation, as well as by direct negative feedback (at 
both the hypothalamic and the pituitary level) by Insulin-like Growth Factor-
1/Somatomedin-C (IGF-1). 
As discussed in the following chapter most, though not all effects of GH are mediated 
by IGF-1 which is synthesized in various peripheral tissues. IGF-1 secreted by the liver 
is the main determinant of plasma IGF-1 levels. 
The release of SMS and GHRH by hypothalamic neurons is influenced by a variety of 
neuropeptides, like Thyrotrophin Releasing Hormone, opioid peptides and Vasoactive 
Intestinal Polypeptide, as well as by neurotransmitters, including acetylcholine, 
dopamine, serotonin, norepinephrine which are relaying signals from neurons in other 
brain areas (6, 7). 
Physiologic conditions known to influence GH secretion (mostly indirectly via 
stimulation or inhibition of the release of GHRH andjor SMS) are: (delta·) sleep (8), 
exercise (9), metabolic signals (like hypoglycemia, proteins (arginine), fatty acids 
10,11), fasting (12), body weight (13), gonadal steroids (14,15), and 
age. 
The effects of age on basal and stimulated GH secretion (and IGF-1) levels have been 
addressed in a number of studies with conflicting results (15,16,17, 
18,19,20,21 ,22,23,24,25). In some studies no age related decline 
of GH secretion was observed (16-19). Some authors used GH stimulation tests, while 
stimulated GH secretion may not represent spontaneous age-related GH secretion. 
Others used groups of patients which might have differed not only in age but also in 
weight and nutritional status which could offset age-related changes. However, in most 
studies an age-related decline in spontaneous (and stimulated) GH secretion was 
found. Accordingly, plasma IGF-1 levels also show an age related decline 
(15,26,27,28,29). 
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Assessment of GH deficiency 
GH secretion in children with short stature possibly due to GH deficiency can be 
assessed either by the measurement of spontaneous GH secretion or with physiologic 
(sleep) or pharmacological (clonidine, arginine, insulin, GHRH) stimulation tests. As the 
24 hour sampling for the measurement of spontaneous GH secretion is cumbersome 
and possibly less sensitive (30), most centres use one or more stimulation tests. 
However, reproducibility of stimulation tests is reportedly low (31 ,32) and their 
value to assess endogenous GH secretion is disputed (33,34). In addition GH 
stimulation by insulin is unpleasant and potentially dangerous. 
The use of GHRH as a stimulator of GH secretion has the advantages of being easy 
to perform and without side-effects (35,36,37,38,39). However, as some 
patients may be GH-deftcient due to hypothalamic or suprahypothalamic disorders, 
these may not be detected by direct stimulation of the pituitary gland with GHRH. 
In older adults the difference between normal and subnormal GH secretion is even 
more difficult to establish, as physiologic GH secretion at this age also diminishes. 
Another approach to the assessment of GH deficiency is the measurement of 
circulating IGF-1 concentrations (40,41). Levels of IGF-1 are relatively constant 
during the day (42). As other factors (nutritional (43,44), hormonal (40), age 
(15,26-29)) influence circulating IGF-1 levels as well, these should also be taken into 
consideration when interpreting the plasma IGF-1 level. 
In conclusion the diagnosis of GH deficiency is usually based on a combination of 
clinical suspicion, two GH stimulation tests showing inadequate (usually a cut off point 
of 7 ugjl is used) rise of GH as well as a lowered plasma IGF-1 level. 
REFERENCES 
1. Wifhelmi AR: Structure and function of growth hormone. ln hormone drugs. Proceedings of the 
FDA/USP workshop on drug reference standards for insulins, somatotropins and thyroid 
hormones. Rockville, MD, US Pharmacological Convention May 18-21, 1982. 
2. Quabbe H-J, Schilling E, Helge H. Pattern of growth hormone secretion during a 24 hour fast 
in normal adults. J Clin Endocrinor Metab 1966;26:1173-7. 
3. Takahashi Y, Kipnis DM, Daughaday WH. Growth hormone secretion during sleep. J Clin Invest 
1968;47:2079·90. 
4. Winer LM. Shaw MA, Bauman G. Basar plasma growth hormone levels in man: new evidence 
for rhythmicity of growth hormone secretion. J CHn Endocrinol Metab 1990;70:1678-86. 
5. Tannenbaum GS, Ung N. The interrelationship of growth hormone (GH)-refeasing factor and 
somatostatin in generation of the ultradlan rhythm of GH secretion. Endocrinology 
1984;115:1952·7. 
13 
6. Dieguez C. Page MD, Scanlon MF. Growth hormone neuroregulation and Its alterations in 
disease states. C!in Endocrinol1988;28:109-43. 
7. Thorner MO, Rogal AD. Neuroendocrine regulation of growth hormone secretion. In: Human 
Growth Hormone. Underwood LE (ed) New York Marcel Oekker,lnc 1988;113-30. 
8. Hall RW, Hartman Ml, Veldhuis JD, Taylor WM, Thorner MO. Thirty second sampling of plasma 
growth hormone in man: correlation with sleep stages. J Clin Endocrinol Metab 1991 ;72:854-61. 
9. lacey KA, Hewison A, Parkin JM. Exercise as a screening test for growth hormone deficiency 
in children. Arch Dis Child 1973;48:508-12. 
10. Merimee T J, Rabinowotz D, Fineberg SE. Arginine initiated release of human growth hormone: 
factors modifying the response in normal man. N Eng/ J Med 1969;280:1434-8. 
11. Muggeo M, Tiengo A, Fedele 0, Crepaldi G. The Influence of plasma triglycerides on human 
growth hormone response to arginine and insulin. A study in hyperlipaemics and normal 
subjects. Harm Metab Res 1975;7:367-74. 
12. Ho KY, Ve!dhuis JD, Johnson ML, Furlanetto R, Evans WS, Alberti KGMM, Thorner MO. Fasting 
enhances growth hormone secretion in man. J Clin Invest 1988;81:968-75. 
13. Veldhuis JD, Jranmanesh A, Ho KKY, Waters M, Johson Ml, Uzarra!de G. Dual defects in 
pulsatile growth hormone and clearance subserve the hyposomatotropism of obesity in man. 
J Clin Endocrinol Metab 1991;72:51-9. 
14. Link K, Blizzard RM, Evans WS, Kaiser Dl, Parker MW, Rogal AD. The effect of androgens on 
the pulsatile release and the twenty-four hour mean concentration of growth hormone in 
peripubertal males. J Clin Endocrine! Metab 1986;62:159-64. 
15. Ho KY, Evans WS, Blizzard RM, Veldhuis JD, Merriam GR Samojlik E, Furlanetto R, Rogel AD, 
Kaiser Dl, Thorner MO. Effects of sex and age on the 24 hour secretory profile of GH secretion 
in man: importance of endogenous estradiol concentrations. J Clin Endocrinol Metab 
1987;64:51-8. 
16. Dudl RJ, Ensinck JW, Palmer HE, Williams RH. Effect of age on growth hormone secretion in 
man. J Clin Endocrinol Metab 1973;37:11-6. 
17. Kalk WJ, Vinik AI, Pimstone Bl, Jackson WPU. Growth hormone response to insulin 
hypoglycemia in the elderly. J Gerontol1973;28:431-3. 
18. Prinz ?N, Weitzman ED, Cunningham GR, Karacan I. Plasma growth hormone during sleep in 
young and aged men. J Gerontal 1983;38:519-24. 
19. Pavlov EP, Harman SM. Merrian GR, Gelato MC, Blackman MR. Responses of growth hormone 
and somatomedin-C to GH releasing hormone in healthy aging men. J Clin Endocrine! Metab 
1986;62:595-800. 
20. Carlson HE, Gillin JC, Gordon P, Snyder F. Absence of sleep-related growth hormone peaks in 
aged normal subjects and in acromegaly. J Clin Endocrine! Metab 1972;34:1102-5. 
21. Finkelstein JW, Roffwarg HP, Boyar RM, Kream J, Hellman L 
Age-related change in the twenty-four hour spontaneous secretion of growth hormone. J Clin 
Endocrinol Metab 1972; 35:665-70. 
14 
22. Rudman D, Kutner MH, Rogers CM, Lubin MF, Flemming A, Bain RP.Impaired growth hormone 
secretion in the aduft population. J Cfin Invest 1981;67:1361-9. 
23. Shibasaki T, Shizume K, Nakahara M, Masuda A. Jibiki K. Demura H. Wakabayashi I, Ling N. 
Age-related changes in plasma growth hormone response to gro'Nth hormone-refeasing factor 
in man. J Clin Endocrine! Metab 1984;58:212-4. 
24. Zadik z. Chafew AC, McCarter Jr RJ. Meistas M, Kowarski AA The influence of age on the 24-
hourintegrated concentration of growth hormone in normal individuals. J Clin Endocrinol Metab 
1985;60:513-6. 
25. Lang I, Schernthaner G, Pietsch mann P, Kurz R, Stephenson JM, Temp! H. Effects of age and 
sex on growth hormone response to growth hormone-releasing hormone in healthy 
individuals. J Clin Endocrinol Metab 1987;65:535-40. 
26. Fiorini JR, Prinz PN, VItiello MV, Hintz RL Somatomedin-C levels in healthy young and old men: 
Relationship to peak and 24 hour integrated levels of growth hormone. J Geront 1985;40:2-7. 
27. Vermeulen A Nyctohemeral growth hormone profiles in young and aged men: correlation with 
somatomedin-C levels. J Clin Endocrine! Metab 1987;64;884-8. 
28. Hammerman MR.InsuHn-like growth factors and aging. Clin Endocrinol Metab 1987;16:995-1 011. 
29. Copeland KC, Colletti RB, Devlin JT, McAuiiTe TL The relationship between insulin-like growth 
factor-!. adiposity and aging. Metabolism 1990;39:584-7. 
30. Rose SR, Ross JL, Uriarte M, Barnes KM, Cassorla FG, Cutler Jr G8. The advantage of 
measuring stimulated as compared with spontaneous growth hormone levels in the diagnosis 
of growth hormone deficiency. N Engl J Med 1988;319:201-7. 
31. Zadik Z, Chalew SA, Giluia Z, Kowarski AA. Reproducibility of growth hormone testing 
procedures: a comparison between 24-hour integrated concentration and pharmacological 
stimulation. J Clln Endocrinol Metab 1990;71:1127-30. 
32. Tassoni P, Gacciari E, Cau M, Com C, Tosi M, ZucchiniS, Cicognanl A, PirazzoH P, Salardi S, 
Balsamo A, Frejavme E, Cassia A, Zappulla F. Variability of growth hormone response to 
pharmacological and sleep tests performed twice in short children. J Clin Endocrine! Metab 
1990;71 :230-4. 
33. Bercu 88, Shulman D, Root AW, SpHiotis BE. Growth hormone (GH) provocative testing 
frequently does not reflect endogenous GH secretion. J Clin Endocrinol Metab 1986;63:709-16. 
34. Chalew SA, Armour KM, Levin PA, Thorner MO, Kowarski AA. Growth hormone (GH) response 
to GH-re!easing hormone in children with subnormal integrated concentrations of GH. J Clin 
Endocrinol Metab 1986;62;1110-5. 
35. Gelato MC, Pescovitz OH, Cassorla F, Loriaux DL, Merriam GR. Dose-response relationships for 
the effects of growth hormone-releasing factor-(1-44)-NH2 in young adult men and women. J 
Ctin Endocrine! Metab 1984;59:197-201. 
36. Schriock EA, Ustig RH, Rosenthal SM, Kaplan SL, Grumbach MM. Effect of growth hormone 
(GH)-releasing hormone (GRH) on plasma GH in relation to magnitude and duration of GH 
deficiency in 26 children and adults with isolated GH deficiency or multiple pituitary hormone 
deficiencies: evidence for hypothalamic GRH deficiency. J Clin Endocrine! Metab 1984;58:1 043-
9. 
15 
37. Rogal AD, Blizzard RM, Johanson AJ, Furlanetto RW, Evans WS, Rivier J, Vale WW, Thorner 
MO. Growth hormone release in response to human pancreatic tumour growth hormone-
releasing hormone-40 in children with short stature. J Clin Endocrlnol Metab 1984;59:580-6. 
38. lang R, Kurz, Geyer G, Tragi KH. he influence of age on pancreatic growth hormone releasing 
hormone stimulated growth hormone secretion. Harm Metab Res 1988;20:574-8. 
39. Albini CH. Reiter EO. Mills BJ, MacGillivray MH. Diagnostic value of the growth hormone-
releasing factor stimulation test. Clin Pharmacal Ther 1988;43:696-700. 
40. Furlanetto RW, Underwood LE, Van Wijk JJ. D'Ercole AJ. Estimation of somatomedin-C levels 
in normals and patients with pituitary disease by radioimmunoassay. J Clin Invest 1977;60:648-
57. 
41. Furlanetto RW. Insulin-like growth factor measurements in the evaluation of growth hormone 
secretion. Harm Res 1990;33(suppl 4):25-30. 
42. Minute F, Underwood LE, Grimaldi P, Furlanetto RW, Van Wijk JJ, Giordano G. Decreased 
serum somatomedin C concentrations during sleep: temporal relationship to the nocturnal 
surges of growth hormone and prolactin. J Clin Endocrinol Metab 1981;52:399-403. 
43. Clemmons DR, Klibanski A, Underwood LE, McArthur JW, Ridgway EC, Beitins IZ, Van Wijk JJ. 
Reduction of plasma immunoreactive somatomedin-C during fasting in humans. J Clin 
Endocrinol Metab 1981 ;53:1247-50. 
44. Isley WL Underwood LE. Clemmons DR. Dietary components that regulate serum somatomedin-
C concentrations in humans. J Clin Invest 1983;71:175-82. 
16 
1.3. GROWTH HORMONE FUNCTIONS 
1.3.1. INCIDENCE OF GH DEFICIENCY IN ADULTHOOD 
Estimated prevalence of GH deficiency in children in the Western World varies, 
depending on the criteria used, between 1 in 4000-5000 (1) and 1 in 30.000 (2). In 
the Netherlands an estimated 1 in 12.000 children are diagnosed to be GH deficient 
(3) and are being treated with (daily) subcutaneous GH injections. Presently GH 
treatment is stopped after these children have reached their final height. 
The incidence of (pan)hypopituitarism, directly or indirectly (after surgical or radiation 
treatment), due to a pituitary tumor in adulthood is unknown. Based on the incidence 
in children it may be assumed that in the Netherlands (with a total population of 15 
million) between 1000 and 2000 adults have growth hormone deficiency. 
Consequences 
Until recently growth hormone deficiency in adulthood, either idiopathic or acquired 
after treatment lor a non malignant pituitary tumor, was thought not to be associated 
with a reduced life expectancy, as long as concomitant other hormonal insufficiencies 
were adequately substituted. However, in a retrospective study of 333 patients with 
hypopituitarism diagnosed over a period of 30 years, Rosen and Bengtsson found an 
increased overall mortality, with a significantly increased risk for death from 
cardiovascular disorders (4). This observation was independent of variables like age 
at diagnosis, the degree of hypopituitarism, the presence of hypertension or diabetes 
mellitus and gender. In addition a reduced risk of death from malignant tumors was 
suggested. The authors suggest that their findings might be due to untreated GH 
deficiency in adulthood. In addition, many endocrinologists have the impression that 
adults with GH deficiency often do not feel welL 
GH secretion does not cease after the epiphyses have fused and final height is 
achieved at the end of puberty. Instead it continues well into the 6th to 7th decade 
(Chapter 1.2.), suggesting that phylogenetically GH apparently is of use in adulthood. 
As will be described below GH plays a role in adulthood in maintaining body 
composition and exercise capacity, in bone, lipid, glucose and thyroid hormone 
homeostasis, in renal, cardiac and immune function, as well as in the maintenance of 
subjective well being. 
1.3.2. GH AND SUBJECTIVE WELL BEING 
Adults with GH deficiency have shown a reduction in social activity andjor 
psychological well being in most (5,6,7,8,9,10) though not all (11) studies. 
As some of these studies included patients who had been treated with radiation 
therapy for their initial disease, and/or were also being treated for other hormonal 
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insufficiencies, it cannot be ascertained in all studies that the abnormalities described 
were due to GH deficiency per se. In addition, as many patients who had GH 
deficiency at childhood had not attained normal height, in spite of GH substitution 
(which was either in an insufficient dose and or frequency or initiated too late), short 
stature may be a contributory factor. 
Another interesting report noted an increase in cognitive psychometric testing during 
GH treatment of adults with GH deficiency due to panhypopituitarism (12). Recently 
a decrease in deep sleep in adults with isolated GH deficiency was observed 
(13, 14). This decrease in deep sleep may be either a cause or a consequence 
of Qsolated) GH deficiency. It may be a contributory factor to the reduced well being 
and performance in adults with GH deficiency. 
1.3.3. GH AND BODY COMPOSITION, MUSCLE MASS AND STRENGTH 
Animal data 
Sonntag et al demonstrated that GH influences protein metabolism in skeletal muscle 
in adu~ rats (15). Administration of excessive amounts of GH to rats, either by 
implantation of GH-producing tumors (16,17) or by sc injection (18) resulted in 
increased growth of skeletal muscle. Ullman et al demonstrated GH-induced muscle 
growth in regenerating muscle after ischaemic injury and diminished muscle atrophy 
after denervation (19). Another study in adult rats showed a change in skeletal 
muscle fibre composition after hypophysectomy, which was reversed after 7 daily 
injections of GH (20). These changes imply a reduction in the capacity of the muscle 
fibres for aerobic metabolism of substrates and a decreased resistance to fatigue in 
adult rat muscle after hypophysectomy. 
Human data 
GH deficiency 
In GH deficient children higher skinfold thicknesses and lower muscle masses or 
muscle widths are found, which are at least partially reversible by GH substitution 
treatment (21 ,22,23,24,25,26,27). In addition GH treatment to GH 
deficient subjects induced redistribution of fat from abdominal to peripheral sites 
(28). After cessation of GH treatment fat mass has been shown to increase and 
muscle mass to decrease (21 ,22,26). 
The administration of GH to adults with GH deficiency leads to an increase in thigh 
muscle volume, measured by cross sectional CT scanning of the quadriceps muscle 
(29,30), and an increase in fat free mass (FFM) and a decrease in fat mass (as 
assessed by hydrodensitometry (31) or total-body potassium 32)). Four months 
of GH treatment (dosage 2 U/m'/d) led to a significant increase in muscle and a 
decrease in adipose tissue mass (compared with a placebo treatment group (29)), 
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while after more than a year of this treatment, the observed changes had further 
increased (30). In the study by Crist et al (31) an increase in FFM of 1.3 kg was 
observed after 2 weeks of GH treatment in 6 GH deficient females who received 700 
ug GH/d sc (or approximately 10 ug GH/kg BW /d). Wrthin the same period FM 
decreased 2.3 kg. In the longer-term study by Solomon et al (32) 6 months of GH 
administration (0.07 U (or:!: 30 ug)GH/kg BW/d) led to an increase of FFM of5.5 kg 
with a concomrtant decrease in fat mass of 5.7 kg. Interestingly the main part of these 
changes was observed within the first month of the 6 months treatment period. 
After cessation of GH treatment in young adults a decrease in thigh muscle volume 
was observed with a simultaneous decrease in quadriceps muscle strength 
(33,34). In another study quadriceps muscle strength in GH deficient adults was 
lower compared with healthy adults, also after correction lor body weight and muscle 
area (35). Exercise capacrty, measured by a cycle ergometry test, in GH deficient 
adults showed a considerable improvement during GH therapy (29,36). 
Physiologic GH secretion 
As described in Chapter 1.4. exogenous GH has clear anabolic effects in catabolic but 
non-GH deficient adults. GH administration (dosage 30 ugjkg BW, three times a week 
for 6 months) to a group of healthy elderly (age >60 yr) men led to a 8.8% increase 
in fat free mass and a 14.4% decrease in fat mass as assessed by total body 
potassium, while in a similar placebo treated group no changes were observed (37). 
GH hypersecretion 
Body composition in acromegalies differs from normal: plasma volume, total body 
water and extra cellular water (ECW) are increased as is total body potassium, 
reflecting a higher FFM and lower FM. Upon successful treatment (GH levels below 
2.5 ugjl) normalisation of ECW, reflecting FFM, and FM have been observed 
(38,39). 
1.3.4. GH AND BONE HOMEOSTASIS 
Growth hormone derives its name from the observation that it is the substance present 
in pituitary extracts responsible for the stimulation of longitudinal bone (and thereby 
body) growth in the young (40,41), completed late in adolescence. (As GH 
deficient children from GH deficient mothers have normal weight and length, fetal 
growth seems GH independent). Growth hormone also plays a role in the active 
process of bone remodelling (resorption and formation) in adulthood. 
The mechanism by which GH influences bone (re)modelling is complex, consisting of 
direct effects of GH and IGF-1 on bone tissue, as well as indirect through effects on 
vitamin D, calcium and phosphorus metabolism. 
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Direct effects of GH on bone. 
The stimulation of longitudinal bone growth in childhood by stimulation of the 
chondrocytes in cartilage and the epiphyseal growth plate, is the result of the 
combined effects of GH and IGF-1 {42). While the somatomedin hypothesis (43) 
postulated that the growth promoting effects of GH are mediated by serum factors, 
now known as IGF-1, extensive evidence indicates that IGF-1 alone is not capable of 
maintaining normal growth in GH deficient animals. In addition, in vitro studies showed 
both the presence of GH receptors on chondrocytes (44), as well as the capability 
of bone cells to secrete IGF-1 {45,46). Results from a study using a rat hind-limb 
perfusion model also suggests that GH stimulates growth through local production of 
IGF-1 (47). This and other evidence (reviewed in 42) indicate that GH stimulates the 
differentiation of prechondrocytes, which makes these cells responsive to IGF-1 (either 
from the liver or locally produced). This further stimulates the clonal expansion of 
differentiating chondrocytes and bone matrix formation (48). Such a sequence of 
events is in agreement with the "dual effector theory" of GH action postulated by Green 
et al (49). 
The ability of GH to stimulate osteoblasts and bone matrix formation can be observed 
by measuring circulating levels of osteocalcin {bone gamma-carboxy glutamic acid· 
containing protein, which is a major non-collagenous protein of bone matrix, secreted 
by osteoblasts (50)) and type I and Ill procollagen (51). 
In GH deficient children lowered pretreatment levels of osteocalcin are normalized by 
GH therapy (52,53) and similar observations were made using type I and Ill 
procollagen as a parameter (54,55). Also, in GH deficient adults normal 
osteocalcin levels increase upon GH administration (56). In acromegalies elevated 
levels of osteocalcin and type Ill procollagen are normalized after successful treatment 
(57,58). 
Effects of GH on calcium and phosphorus metabolism. 
Older studies, using crude pituitary extracts, showed an increase in intestinal calcium 
absorption and urinary calcium excretion, when GH was administered to hypopituitary 
patients for several days to weeks (59,60,61 ). 
In acromegalies similar effects were observed (62,63), while others demonstrated 
increased levels of 1 ,25-dihydroxyvitamin D, reversible upon treatment 
(64,65,66). Therefore it was postulated that GH exerts its effect via increased 
synthesis of 1 ,25 dihydroxy-vitamin D, possibly by stimulation of renal 1-a-hydroxylase 
activity (65,66). 
However, in GH deficient children both acute (67) and chronic (68,69) 
administration of relatively low doses of GH, sufficient to induce calcium and 
phosphorus retention, did not result in a rise of plasma 1 ,25-dihydroxyvitamin D levels. 
Another study in GH deficient children showed that a higher GH dosage was capable 
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to induce a raise in 1 ,25-dihydroxyvitamin D within 5 days, while chronic administration 
of a lower dose of GH did not induce changes in 1 ,25-dihydroxyvitamin D; meanwhile 
urinary cAMP output increased without measurable changes in iPTH (70). 
Therefore, it appears that while physiologic GH levels stimulate intestinal calcium 
absorption directly and increase the sensitivity of the kidney to PTH (although 
insufficient to compensate for the increased intestinal calcium absorption, thereby 
increasing urinary calcium excretion), pharmacological amounts of GH increase 
intestinal calcium absorption indirectly by raising 1 ,25-dihydroxyvitamin D levels. 
Research in animals and in GH deficient children indicates that both the effects of GH 
on renal phosphate handling and on 1 ,25-dihydroxyvitamin D synthesis are mediated 
by IGF-1 (71, 72). Furthermore there is also evidence that estrogens and 1,25-
dihydroxyvitamin D exert at least some of their anabolic effects on bone through the 
local stimulation of IGF-1 synthesis (73) or via an increase in IGF-1 binding sites 
{74). 
Clinical consequences in adulthood. 
No data on bone mineral mass in adults with isolated GH deficiency compared with 
age and sex matched controls are available. Results from a pilot study in 8 GH 
deficient patients showed a significant increase in bone mineral density of the lumbar 
spine after 16-24 weeks of daily administration of 6 U of GH over a period of 32 to 40 
weeks {75). Circulating osteocalcin and urinary hydroxy-proline excretion increased 
during GH treatment. In healthy adult men 7 days of GH administration (in a high 
dose) led to an increase in osteocalcin and bone alkaline phosphatase levels, which 
persisted for 6 months thereafter. However, elevated urinary OH-proline excretion 
returned to normal within 4 weeks (76). One week of GH treatment apparently 
stimulates osteoblasts and activates bone remodelling lor a longer period of time. 
In an older study of 7 women with postmenopausal osteoporosis no increment in bone 
mass could be observed after 6 months of daily GH administration (77). More 
recently GH treatment for 2 months, followed by calcitonin for 3 months and a 
medication free period of 3 months was shown to increase total body calcium in 7 
women {78). However, an increase in bone mineral content at the radius did not 
reach significance. 
The net effect of GH excess on bone mineral mass (assessed by single and dual 
photon absorptiometry) appears to be site specific: In a study of 24 acromegalies 
forearm bone mineral mass (mainly cortical bone) was increased, while vertebral bone 
mass (mainly trabecular bone) was decreased when compared with age and sex 
matched controls (79). 
In summary, the effects of GH on bone are complex and appear partially contradictory. 
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1.3.5. GH AND CARBOHYDRATE AND LIPID HOMEOSTASIS 
As extensively reviewed in ref 80 the in vitro and in vivo effects of GH on 
carbohydrate and lipid metabolism can be separated in insulin-like and anti-insulin-like 
effects. 
In vitro studies. 
In the first hours of incubation of adipose and muscle tissue, derived from 
hypophysectomized rats, with GH glucose uptake and oxidation increase, while 
lipolysis decreases. Prior exposure of these tissues to GH diminishes these insulin-like 
effects. Likewise, tissues from intact rats did not show an insulin-like response to 
incubation with GH. Anti-insulin-like effects can be observed, however, after 2-4 hours 
of GH incubation in tissues derived from hypophysectomized rats: glucose uptake and 
oxidation decrease while lipolysis increases. 
In vivo, GH deficient states. 
Chronic GH deficiency in animals and humans (81 ,82) causes decreased fasting 
glucose concentrations (due to decreased hepatic glucose output), decreased insulin 
secretion and increased insulin sensitivity (due to increased glucose utilization and 
blunting of the increase in hepatic glucose output in response to falling glucose levels). 
In addition, GH deficiency is associated with hypercholesterolaemia 
(83,84,85,86) though, according to one study (87), this occurred only in 
GH deficient subjects with a positive family history for hyperlipidaemia. 
In vivo, insulin-/ike effects. 
Similarly to the above mentioned in vitro effects, GH administration to 
hypophysectomized dogs, rats and GH deficient children (88) leads to a rapid but 
transient (lasting an hour) decrease in glucose and FFA concentrations. In normal 
fasting animals and humans (89) these short-term effects could also be observed. 
Under physiological circumstances these short-term insulin-like effects are probably 
not of great importance, as the endogenous secretion of GH, during daily activity and 
after the onset of sleep, induces a refractory state of its insulin-like effects during day 
and night. 
In vivo, anti-insulin-like effects. 
Chronic GH administration to hypophysectomized animals raised fasting glucose 
concentrations, further impaired glucose tolerance in spite of increased insulin levels, 
and decreased insulin sensitivity. 
In intact animals the anti-insulin-like effects of GH (e.g. increased lasting glucose and 
insulin concentrations, as well as increased insulin levels after pharmacological 
stimulation) can be observed within several hours after the first injection as well as 
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during daily GH injections. GH administration hampers both the ability of insulin to 
depress hepatic glucose production as well as to stimulate glucose uptake. In a study 
in normal dogs GH administration for several months led to permanent diabetes 
mellitus, which was not reversible after the discontinuation of GH (90). 
In GH deficient children given GH fasting glucose levels, insulin levels, hepatic glucose 
output, as well as FFA levels increased (81 ,82,91), while cholesterol levels 
decreased in some (84,85) though not all (87,92,93) studies. 
Depending on the GH dose administered to healthy humans fasting glucose 
concentrations were either normal (94,95,96) or elevated (97), with increased 
fasting (94,95) or glucose load-stimulated (96) insulin levels. In normal subjects the 
anti-insulin-like actions of GH occur both at hepatic and peripheral sites. Cholesterol 
levels decreased (98) or did not change (99) during GH administration in healthy 
humans. 
In acromegalies abnormal GH secretion causes hyperinsulinism (1 00,101, 
1 02) and insulin resistance, both peripheral (1 03) as well as at the hepatic level 
(104). After surgical (101) or medical (102) therapy of acromegaly, carbohydrate 
metabolism improved. The degree of improvement was inversely related to the 
duration of the disease as well as to the height of both pre- and post- operative GH 
levels. Mediated by the elevated insulin (1 05) and decreased lipoprotein lipase 
(1 06) levels found in acromegalies serum triglycerides are usually increased, and 
return to normal after therapy (105). 
Conclusions. 
As prior exposure to GH hampers the insulin-like effects (enhanced glucose utilization 
and antilipolysis) of GH, they are of little physiologic importance, although 
hypoglycaemia may develop in long-term GH deficient patients after the first GH 
injection. 
The anti-insulin-like effects observed during chronic exposure to GH, involve impaired 
glucose utilization and increased hepatic glucose output. These are of clinical 
importance in chronic states of elevated GH levels such as acromegaly, diabetes 
mellitus and during chronic administration of GH to non-GH deficient adults. 
The effects of GH on circulating cholesterol and triglycerides are of little physiologic 
importance, though they may contribute to elevated cholesterol levels in GH deficiency 
and elevated triglyceride levels in acromegaly. 
1.3.6. GH AND OTHER HORMONAL FUNCTIONS 
Thyroid hormones. 
Thyroid function is probably influenced in several ways by the presence or absence 
of GH. Firstly the TSH response to TRH is increased and prolonged in children with 
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idiopathic GH deficiency (107,108,109,110,111,112), while 
hypothyroidism and reduced TSH response to TRH have been reported after 
therapeutic administration of GH (108-111). In addition, in acromegalies the TSH 
response to TRH is low (113, 114,115, 116). The paradox of pituitary 
disease Onducing GH deficiency) and an increased TSH response to TRH was further 
demonstrated in a study by Cobb et al (117), which suggested that endogenous 
GH depresses the TSH response to TRH while enhancing thyroid secretion of T3 in 
response to the evoked TSH release. 
Secondly, IGF-1, not GH, has distinct growth promoting effects on thyroid follicular 
cells, though it is more likely that paracrine mediated IGF-1 (118,119) (probably 
under the influence of TSH and not of GH) and not plasma IGF-1 levels (mediated by 
GH) are of importance in this regard. 
Thirdly, there is evidence, both from the older (11 0, 120, 121) and more recent 
(122, 123) literature, that GH influences the peripheral metabolism of T4 and T3. 
In a short term study in healthy adults given 125 ug GH/kgjday for four days a GH-
induced increase in peripheral deiodination of T4 to T3 was observed (122). Similar 
observations were reported when GH deficient adults were treated with a somewhat 
lower dose of 2 U (667 ug) GH/m' lor 4 months (123). 
GH may exert this effect either directly or indirectly through the generation of IGF-1. In 
normals fasting induces an increase in GH (124) and a decrease in IGF-1 levels 
(125,126, 127,128), while T3 levels decrease due to a reduction in the 
peripheral conversion of T4 to T3 (129). Releeding induces an increase in JGF-1 
(126-128), as well as an increase in T31evels and a decrease in rT3 production (129). 
Therefore IGF-1 and not GH itself might stimulate the peripheral conversion of T4 to T3 
during GH treatment of GH deficient adults. It is tempting to speculate about which 
influence GH deficiency and treatment thereof have on body composition via the 
changes in circulating T3 levels mentioned above. 
Gonadal hormones 
Gonadal function in patients with isolated GH deficiency is normal (86). However GH 
treatment of non-GH deficient women who did not respond to gonadotrophin treatment 
in an in vitro fertilization program, leads to super-ovulation (130), related to marked 
increases of the IGF-1 levels in follicular fluid (131). 
Extensive literature has appeared which shows an important modulating (para- and 
autocrine) role, of IGF-1 in the function of the ovaries. Fertility in GH deficient mice is 
restored by GH treatment (132). In vivo GH enhances IGF-1 production by human 
granulosa cells (133), while in vitro JGF-1 stimulates the production of estradiol 
(134) by granulosa cells. Granulosa cells have specific IGF-1 receptors (135), 
which can be upregulated by FSH (136). 
In males, similar observations indicating that testicular IGF-1 levels are regulated by 
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locally acting GH rather than by hepatic IGF-1 production (137, 138), have been 
made. 
In conclusion,~ appears that GH deficiency itself is not of major importance in normal 
gonadal function in adulthood and that most effects GH may have are mediated by 
locally produced IGF-1. 
1.3.7. GH AND THE CARDIOVASCULAR SYSTEM 
Cardiac function 
Animal data 
In hypophysectomized rats hearts fail to respond adequately to aortic binding, as 
those rats do not develop cardiomegaly (139). In contrast, normal rats bearing a 
GH-secreting tumor develop an increase in ventricular weight {140, 141). 
Haemodynamic atudies, performed 2-4 months after tumor implantation in normal rats, 
showed an improvement in cardiac function, also when corrected for cardiac weight 
(140). Cardiac contractility increased in parallel to changes in myosin composition 
(141). Evidence from studies by Guier eta! indicates that the effects of GH on cardiac 
weight in hypophysectomized rats are mediated by, probably locally produced 
{142), IGF-1 (143). However, the GH induced fluid retention may contribute to 
the observed haemodynamic changes. 
Human data 
In a group of 333 hypopituitary patients (from which patients with acromegaly and 
Cushing's disease were excluded), who had received adequate replacement therapy 
with thyroid, gonadal andjor adrenocortical hormones, premature mortality due to 
cardiovascular disease was noted, which was possibly attributable to longstanding GH 
deficiency ( 4). 
GH therapy led to a dramatic improvement of cardiac function in a 53 yr old patient 
with severe cardiac failure and probable (though not proven) GH deficiency {144), 
while in a group of 22 GH deficient adults treated for 4 months, an improvement in 
cardiac function was suggested (29). In normal adult volunteers (145) an increase 
in echocardiografically assessed myocardial contractility was noted after i week of GH 
administration, which had reversed within 1 week after stopping GH. In humans 
treatment with GH enhances myosin heavy chain MRNA accumulation in skeletal 
muscle (146). As in the rat data it is difficult, at present, to determine which effects 
are caused by GH itself, which are mediated by locally produced IGF-1 and which are 
secondary to an increase in preload. 
Acromegalies have left ventricular hypertrophy (147,148,149), while in 
longstanding acromegaly heart failure, secondary to hypertension and coronary artery 
disease, is a frequent complication (i50,i5i,i52). In a study comparing 12 
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patients with recently developed active acromegaly (mean duration estimated at 6 
years) without hypertension or diabetes mellitus, with an age- and sex-matched control 
group an increase in myocardial contractility, cardiac output (due to both increased 
heart rate and stroke volume) with a reduced afterload and normal preload was 
observed in the acromegalies (153). Treatment with octreotide of 9 acromegalic 
patients led within 6 months to a decrease in systolic and diastolic blood pressure and 
to a reduction of left ventricular wall thickness, though after 12 months of medical 
therapy left ventricular wall thickness was still increased compared with controls 
(154). 
Growth hormone excess apparently causes an initial improvement in myocardial 
function (so called "hyperkinetic heart syndrome"), which is in the long run followed 
by an increase in blood pressure. This seems similar to the model according to which 
essential hypertension starts out with increased cardiac output with normal or low 
peripheral resistance, progressing by adaptive changes to increased peripheral 
resistance (155, 156) and eventually cardiovascular disease. 
Renal function 
Animal data 
The stimulating effect of GH on kidney growth in normal and hypophysectomized rats 
as well as the compensatory growth after unilateral nephrectomy is at least partially 
mediated by locally produced IGF-1 (143,157,158). In the rat IGF-1 also plays 
a role in the regeneration of the proximal tubuli after ischaemic injury (159). As 
extensively reviewed by Hammerman, GH and IGF-1 regulate glomerular filtration rate 
(GFR), renal plasma flow (RPF), phosphate transport and gluconeogenesis in the intact 
kidney (160). Receptors for GH have been found in the proximal tubule, IGF-1 
receptors are found in the proximal tubule and glomerulus. 
Human data 
Studies in GH deficient humans demonstrated normalization of previously reduced 
(when compared to an age-matched control group (29)) GFR and RPF, as well as an 
increase in creatinine clearance 
(32) after 4-6 months of GH replacement therapy. In normals given GH for 1 week 
(raising GH levels to the level observed in diabetics) GFR and RPF increased to a 
similar extent as observed in the early stages of diabetic nephropathy (161 ). In 
normals ingestion of protein stimulates GH secretion (162) and induces an increase 
in GFR (163), while the latter effect can be blocked by octreotide (164), 
presumably by reducing GH (or glucagon) secretion. As in rats, evidence exists that 
the effects of GH on the human kidney are mediated by auto- and paracrine acting 
IGF-1 (160,165,166,167). Involvement of the renin-angiotensin system is 
unproven as one study in normal men showed that the GH-induced rise in GFR could 
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not be blocked by enalapril (168). 
In patients with acromegaly GFR and RPF expressed per body surface area are 
reported to be increased by 28"/o, when compared with a group of normal age- and 
sex-matched subjects (169), while after hypophysectomy a decrease in RPF, GFR 
and renal mass was reported (170). 
Fluid and sodium homeostasis 
From the early beginning of GH research four decades ago a marked sodium- and 
fluid-retaining effect of GH administration in man has been observed (59,60,61, 171, 
172,173,174). While initially GH-induced mineralocorticoid release was 
postulated to account lor the sodium retention (173), others could not detect an 
increase in aldosterone after GH injection in healthy men (172). In addition other 
studies showed similar sodium-retaining effects in adrenalectomized rats (171) and 
man (174), thereby making this theory less likely. 
A direct effect of GH itself was shown by Ludens et al who observed transient sodium 
retention in the first 6 hours after GH injection to adrenalectomized rats, an effect 
which could be blocked by the administration of actinomycin-D. an RNA synthesis 
inhibitor (175). However, Rabkin et al found no acute effects (within 3 to 5 hours) 
of highly purified GH in rats and normal men (176). 
The limitations of the early studies (partly performed before the species specificity of 
GH was known, using impure pituitary extracts potentially containing vasopressin, as 
well as insensitive aldosterone assay's) led to renewed interest into the "aldosterone 
hypothesis": Ho and Weisberger showed in 6 healthy young men given a large GH 
dose (0.2 U (75 ug) /kg/d) lor 5 days, a clear increase in plasma renin activity and 
a seven fold increase in aldosterone levels (177). A recent report by Moiler et al 
demonstrated in 8 healthy males after two weeks treatment with 12 U (4 mg) GH/day, 
increased extracellular volume and unchanged plasma volume when compared with 
placebo treatment (178). Simultaneously circulating Atrial Natriuretic Peptide (ANP) 
levels decreased and aldosterone levels increased in 7 of the 8 subjects (though the 
mean increase did not reach significance). As ANP is known to inhibit aldosterone 
production, these observations might frt into the same picture. These effects, using 
relatively short term GH excess, could not be demonstrated in acromegaly: untreated 
acromegalies were found to have lowered plasma renin activity (179), and normal 
levels of ANP were found in the presence of elevated plasma volume, when compared 
with treated acromegalies and normal controls (180). 
Evidence for a direct effect of GH on the cellular (renal and elsewhere) NajK pump 
has been reported by Ng and Evans (181). They demonstrated an increase in 
ouabain-sensitive Na efflux in leucocytes from patients with active acromegaly, while 
after successful treatment no difference with normal controls was observed. In 
addition, the ouabain-sensitive Na efflux of normalleucocytes could be stimulated after 
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incubation with 25 mU GH/1 for 1 hour. An older study in rats receiving GH for 7 days 
had shown a GH-induced stimulatory effect on NajK ATP-ase in kidney, brain and liver 
homogenates (182). Perhaps secondary to this primary effect of GH, which leads 
to volume expansion, an increase in endogenous digitalis-like !actor was observed in 
untreated acromegaly (183). This could normalise the cellular sodium pump activity 
(184), a mechanism which might be similar to that reported in essential 
hypertension (185). 
In conclusion the pathophysiology of short term GH excess on sodium and fluid 
retention, as well as the chronic situation of volume overload andjor hypertension in 
acromegaly (186) are not yet completely understood. 
For the GH deficient adult, a reduced risk of hypertension apparently is of lesser 
importance in the development of cardiovascular disease (4) than the increase in 
cholesterol levels. 
1.3.8. GH AND IMMUNE FUNCTION 
Introduction 
In mice GH deficiency is causally related with a wasting disease with recurrent and 
ultimately fatal infections. As extensively reviewed (187) both in vivo Qn animals) 
and in vitro GH deficiency and GH administration have been shown to affect various 
components of the immune system like thymic growth (188), the number of 
peripheral T and B cells (189), antibody synthesis (190), natural killer cell 
activity (191), the priming of macrophages !or the release of superoxide anion 
(192) and neutrophil differentiation (193). 
Immune function in GH deficient adults. 
In humans no clinically apparent immunedeflciency syndrome leading to increased risk 
of infectious diseases is associated with isolated GH deficiency. Levels of circulating 
immunoglobulins, proportion of B cells and T cell subsets and mitogenic response are 
reported to be normal in GH deficient humans (194, 195,196,197, 
198,199). Several alterations in the immune system of GH deficient humans 
have been reported, however: a reduction in natural killer cell activity (194, 195), 
defective synthesis of antibodies in response to antigen (200), defective antibody-
or cell- mediated immunity in vivo (201) and in vitro (198) and the inability of 
lymphoid cells to stimulate cells in an allogenic mixed lymphocyte reaction (202) 
among others (187). 
There is evidence for an auto- or paracrine interaction as there are not only GH 
receptors on human peripheral mononuclear cells (203), but there is also evidence 
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for the capability of mononuclear leucocytes to secrete GH (204) and B 
lymphocytes to secrete IGF-1 (205). 
Effects of GH administration to GH deficient subjects. 
GH administration to GH deficient children with normal pre-treatment T lymphocyte 
subsets led to a temporary increase (after 3-6 months of therapy) in CDS and CDS and 
a decrease in CD4 cells, while after 9-12 months of treatment lymphocyte subsets had 
returned to normal pretreatment distributions (198). Simultaneously in vitro lgM 
production steadily increased from subnormal to normal levels after 9-12 months of 
GH treatment (198). In another study (199) GH substitution of GH deficient children 
induced minimal effects (a decrease in the number of B cells and a transiently 
increased reactivity to phytohemagglutinin stimulation), while in another report (195) 
short-term administration of neither GH nor GHRH induced an increase in natural killer 
cell activity, which in that study was found to be decreased before the initiation of 
therapy. In yet another study natural killer cell activity in women with impaired GH 
secretion increased after 14 days of GH administration (31), while GHRH was found 
to inhibit chemotaxis of peripheral blood leucocytes obtained from normal subjects 
(206). 
Effect of immune function on the GHRH-GH-JGF-1-axis. 
Apart from effects of GH and GHRH on immune function there is also evidence for 
effects of immune activity on the GH-IGF-1 axis. In septic patients IGF-1 production after 
exogenous GH is reduced (207), while in vitro cytokines (tumor necrosis factor and 
interleukin-1b) reduce spontaneous and stimulated GH secretion by cultured rat 
pituitary cells, either directly at the pituitary level (208), and/or indirectly by 
increased somatostatin release from the hypothalamus (209). 
In conclusion, while GH deficiency in man causes no clinically apparent dysfunction 
of the immune system, GH appears to modulate various functions of the immune 
system. 
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1.4. GROWTH HORMONE AS AN ADJUNCT TO THE NUTRITIONAL TREATMENT 
OF CATABOLIC DISEASES 
Effects of (par)enteral (hyper) alimentation. 
The administration of nutrients to a catabolic individual (be it due to infection and 
sepsis, trauma, burns or cancer) to improve his/her nutritional status appears logical, 
as loss of body protein is associated with immunosuppression (thereby increasing the 
incidence of infection) (1), poor wound healing (2), respiratory muscle weakness 
(3) and impaired muscle function causing decreased ambulation (4) and 
consequently increased mortality. 
The problem of delivering the nutrients to the severely ill individual, often incapable of 
normal food intake or gastric tube feeding due to (often temporary) intestinal 
dysfunction was solved after the development of long-term total parenteral nutrition by 
the infusion of hypertonic nutrient solutions via a central venous catheter (5). 
Improved nitrogen balance and patient outcome were reported in a number of open 
studies and reviews (6,7,8). However, over the last decade the efficacy of 
nutritional support in reducing morbidity and mortality has been questioned, while 
complications of the placement of central venous canulae, although infrequent in 
experienced hands, and complications due to bacterial contamination of these canula's 
leads to serious morbidity (9,10,11,12). 
In a study of 8 adult intensive care (ventilator dependent) patients, 10 days of 
aggressive intravenous nutrition did not prevent protein loss, while body weight 
increased due to gains in body fat and water (13). In another, larger, study (14) 
the incidence of postoperative (within 90 days) complications was compared in 395 
malnourished adult patients undergoing major abdominal or thoracic surgery 
randomised to receive perioperative (10-18 days) total parenteral nutrition (TPN), or 
no perioperative TPN. The rates of complications and mortality were identical in both 
groups. In subgroup analysis a reduction of postoperative complications could only 
be observed in the most severely malnourished patients. The use of GH to enhance 
the efficiency of nutrient utilization and to promote protein anabolism in malnourished 
and for metabolically stressed individuals might lead to reduced morbidity, shortened 
reconvalescence and reduced mortality (15). 
Effects of GH administration on nitrogen balance. 
Normal volunteers 
In healthy volunteers on hypocaloric feeding (500 kcalfday) it could be demonstrated 
that 10 mg, recombinant DNA-derived, GH daily, stimulated protein synthesis and fat 
oxidation, enhanced nitrogen and mineral metabolism and resulted in a positive 
nitrogen balance (16, 17). In another study the acute muscle protein response to 
a 6 hr infusion of GH was investigated in the limbs of nutritionally depleted subjects 
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during a period of intravenous refeeding. A significant increase in limb aminoacid 
uptake and in muscle myosin heavy-chain mRNA were observed (18). 
In obese, but otherwise healthy women who were fed hypocaloric diets with adequate 
protein administration of GH (0.05 mgjkg ideal body weight (IBW) every other day or 
0.1 mgjkg IBW /d) for several weeks led to improved nitrogen retention 
(19,20,21). The higher GH dose led to a higher and more prolonged effect on 
nitrogen retention, though after 5 weeks of this treatment no nitrogen retention was 
observed anymore in subjects receiving 18 kcaljkg IBW/d. 
Patients with pituitarv disease 
Using pituitary derived GH, Henneman et al observed nitrogen retention, to a 
maximum of 5-8 g Njday, in all 10 investigated subjects, some of whom had 
hypopituitarism (22). In similar populations and also using pituitary derived GH 
others also observed nitrogen retention, though to a lesser extent (23, 24). Mean 
nitrogen retention was two fold higher in a group of hypopituitaric dwarfs when 
compared with control children when both were given 2 mg GH/kg BW for 5 days 
(25). 
Patients with burns 
In 5 patients with severe burns, Liljedahl et al observed an increased nitrogen 
retention, which was mainly due to an increased dietary intake, when pituitary GH (1 0-
20 mgjd) was administered lor a period of 7 to 9 days, 2 to 3 weeks after injury 
(26). However, in a later study it was found that pituitary GH (4-8 mgjd) 
administration lor 1 week was of little benefit (as to nitrogen retention) in the catabolic 
phase ( + 1- 3 weeks) alter injury, while later, in the anabolic phase ( + 1- 10 weeks), 
nitrogen retention did increase during GH administration (27). Wilmore et al gave 5 
mg GH/d for 1 week to nine severely burned patients 2-35 weeks alter injury and 
observed retention of nitrogen and potassium in the same ratio as the ratio in lean 
tissue (28). 
More recent results from a randomized, double-blinded, placebo controlled trial in 17 
adult patients showed that the daily administration of 10 mg GH enhanced the healing 
of the split-thickness skin graft donor sites (29). Furthermore GH, 0.2 mgj kg/d, 
was shown to improve donor-site healing and to reduce mean hospital stay by 14 
days in a double blind-placebo controlled study in severely (60% of body surface area) 
burned children (30). 
Patients with !surgical) trauma 
Using 2.5-10 mg, pituitary-derived GH for 5 days in 4 patients Johnston and Hadden 
found no effect on protein catabolism in the immediate postoperative period alter 
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herniorrhaphy (31). More recently, however, an anabolic effect cf recombinant DNA 
derived-GH was demonstrated in the post-surgical state in several studies 
(32,33,34,35,36,37). In the first placebo controlled study by the group 
of Sim in patients after major gastrointestinal surgery, receiving 5% glucose infusions 
(to a total of 500 kcal/d), 0.1 mg GH/kg/d in the first 6 postoperative days was shown 
to reduce nitrogen loss, increase fat oxidation and reduce protein oxidation while 
protein turnover (both synthesis (by 209%) as well as breakdown (by 170%)) increased 
(32). In a second study by the same group, mainly differing from the first in the fact 
that the patients received by vein 7 g of nitrogen and 450 kcal of fat in addition to the 
500 kcal glucose, comparable results were observed. The main difference between 
both studies was that even on this limited amount of nutrition GH was able to induce 
nitrogen retention (33). In the third study by this group, now studying the effect of GH 
(0.1 mg/kg/d for 1 week) in patients on full intravenous nutrition, again increased 
nitrogen retention was observed. However, no increase in fat oxidation was 
demonstrated, perhaps due to the higher insulin levels (which tend to inhibit lipolysis) 
occurring in this study (36). In the first study by Wilmore's group (34) 10 mg GH/d for 
1 week (compared with a placebo week in the same patients) in 11 severely 
malnourished post-surgical patients receiving hypocaloric (60%) intravenous nutrition 
was shown to induce nitrogen (3.5 g/d) and phosphorus (220 mg/d) retention. In a 
follow-up study in 6 of the original11 patients similar effects were observed during the 
whole GH treatment period of 13-25 days. In a double blinded placebo controlled 
study in 18 post gastrectomy ;colectomy patients, receiving 1 g protein and 20 kcaljkg 
BW, using less GH (0.06 mgjkg/d during the first postoperative week) nitrogen loss 
was reduced (though not abolished), lean body mass and hand grip strength were 
maintained vs a reduction of both in the controls (35). In a mixed (severe burn/vehicle 
trauma) study population, receiving lull intravenous nutritional support, 10 mg GH/d 
for 1-6 consecutive weeks led to sustained nitrogen, phosphorus and potassium 
retention, when compared with the previous control week in the same patients (37). 
It should be kept in mind, however, that sofar no study (except ref 30) demonstrated 
improved clinical outcome. As 1 gram of nitrogen retention, if completely used by the 
body for muscle conservation/regeneration, stands for only 50 gram of lean tissue, a 
positive nitrogen balance of for example 3 g/d for 1 week translates into circa 1 kg of 
lean body mass, or only 5% of lean tissue. 
Lastly, an interesting observation for gastrointestinal surgeons was made in a rat 
model where (human) GH, 2 mg(!) /kg/d started 1 week before left colonic resection 
and continued until death, was shown to increase the strength of colonic anastomosis 
(38). 
Other possible useful indications 
In healthy volunteers on a normal enteral diet GH, 0.1 mgjkg/d, was able to prevent 
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the catabolic side-effect cf prednisone, 0.8 mgjkg/ d. Prednisone alone induced a 
nitrogen balance of -0.25 mgjkg LBM/d, due to increased protein degradation, while 
in controls nitrogen balance was +0.25 mgjkg LBM/d. GH alone caused a balance 
of +0.60, while GH and prednisone together led to a nitrogen balance of + 0.25 mgjkg 
LBM/d (39). 
In another study GH (30 ugjkg/d for 3 days followed by 60 ugjkg/d for 3 days) was 
administered to malnourished elderly adults with chronic obstructive pulmonary 
disease on total parenteral nutrition. The higher GH dosage induced an increase in fat 
oxidation and a nitrogen retention of circa 2 gjd. No changes in hand grip or 
respiratory muscle function occurred in this short term study (40). 
The mechanism of GH induced anabolism 
Probably several mechanisms contribute to the anabolic effect of GH. Firstly, GH itself 
has a direct effect on lipolysis (see chapter 1.3.5) and on cellular protein synthesis 
(18). Secondly IGF-1 (which in practically all studies described above rose during GH 
treatment), either released from the liver in the circulation or locally produced in the 
tissues (41 ,42,43,44) mediates the anabolic effects. Thirdly, some of the 
anabolic effects of GH treatment could also be explained by increased (mainly in the 
higher GH dosages used) insulin levels (43). However, since the increase in insulin 
levels is at least partly caused by insulin resistance, this increase in levels may not 
represent increase in insulin effects. 
Side effects 
As discussed in chapters 1.3.5. and 1.3.7. hyperglycaemia and fiuid retention appear 
to be the major adverse effects during relatively short-term GH treatment, while the use 
of GH in patients with cancer seems unwise at present, as discussed in chapter 1.5. 
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1.5. GROWTH HORMONE AND CANCER 
As described in chapter 1.4. GH can be used to induce an anabolic state in many 
catabolic conditions. Cancer-induced cachexia diminishes the quality of life significantly 
and the amount of weight loss in cancer patients is positively correlated with their 
overall mortality. In addition, improvement of nutritional status may reduce 
chemotherapy-related toxicity, as has recently been shown in a rat model (1 ). The 
usefulness of (par)enteral (hyper)alimentation in the management of cancer patients 
is controversial (2,3,4,5,6,7). Since one of the causes of cancer-induced muscle 
wasting appears to be reduced protein synthesis combined with unchanged 
degradation (8), GH treatment might be tried as an adjunct to nutrition to prevent or 
diminish cancer-induced cachexia. However, GH administration might stimulate 
tumorogenesis and tumor growth. In a rat model hypophysectomy led to decreased 
tumor growth, reversible by suppletion with thyroxine and GH. One report by 
Svaninger et al (9) demonstrated no improvement of body composition and muscle 
wasting (nor an increase in tumor growth) by GH administration in adult, non-growing, 
sarcoma- bearing mice, while in hypophysectomized rats GH administration stimulated 
body and tumor growth to a similar extent. In their sarcoma tumor model in intact 
animals GH levels were elevated from day 8 after tumor implantation, which was 
explained by the authors as a way to promote endogenous substrate mobilization. 
Unfortunately IGF-1 levels were not reported. 
Human data 
Follow up for 5-30 years of a group of over 300 hypopituitary patients (substituted for 
thyroid, adrenal and gonadal deficiencies) showed a reduced mortality by malignant 
diseases (10). According to some (11, 12) GH treatment in GH-deflcient children 
might be followed by an apparent increased incidence of leukaemia, though disputed 
by others (13). Growth hormone therapy in children, who became GH deficient due 
to radiation therapy for brain tumors or leukemia, apparently does not induce an 
increase in tumor relapse {14, 15). The incidence of neoplasms (colon, breast) in 
retrospective surveys of relatively large numbers of patients with acromegaly of varying 
activity after treatment, is found to be increased in most (16,17,18, 
19,20,21) though not all (22) reports. Several reports indicate that at least 
some tumors cause GH levels to increase (23,24). 
In vitro data 
Evidence is accumulating that GH influences tumorogenesis and tumor growth 
indirectly through locally andjor systemically produced IGF-1. Specific binding sites for 
IGF-1 have been found in several breast tumor cell lines and tissues 
(25,26,27,28,29), colonic (28), and glial (30) tumor tissue, hematologic 
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(31,32,33), and other cancer cell lines (34,35,36). Tumor cells were 
shown to have increased binding capacity to IGF-1 receptors when compared with less 
dedifferentiated eel/lines or with normal surrounding tissue (26,30,32,33,35). IGF-1 is 
produced by breast (37,38), lung (39,40) and colonic (41) tumor tissue or 
eel/lines. 
Increased DNA synthesis and cell growth in response to IGF-1 has been reported for 
many tumor types (26,28,31 ,33,34,37,42,43,44). In sarcomas, liver and renal 
tumors IGF-11 appears to have similar para- and/or autocrine effects, as reviewed in 
ref 45. 
In addition, a direct tumorgrowth stimulatory effect of GH itself was demonstrated 
when it was found that GH directly induces the expression of the c-myc oncogene in 
a lymphoma cell line (46). 
In conclusion, strong arguments can be derived from the studies mentioned above to 
argue against the use of GH (or IGF-1) to promote anabolism in patients with a recent 
history of cancer, tempting as it may be from a clinical standpoint during cancer 
cachexia. 
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1.6. METHODS OF BODY COMPOSITION ASSESSMENT 
Body composition can be assessed using models in which the body is viewed as 
consisting of either two or four compartments. Most methods use the two 
compartment model in which the body consists of a chemically distinct fat and fat free 
(or lean body) mass. The fat mass is anhydrous, potassium free and has a density of 
0.900 gjml at 37C, while the fat free mass is assumed to have a relative constant 
density of 1.1 gjml at 37C, a water content of 72·74%, a potassium content ol60-70 
mmoljkg in men and 50-60 mmoljkg in women. Fat free or Jean body mass can be 
divided in extracellular mass (ECM) and body cell mass (BCM, the metabolic active 
compartment). In the four compartment model the body consists of water, protein, 
bone mineral or fat. 
Methods of body composition assessment can be classified as traditional, using the 
two compartment model or as recent, some of which are capable to determine the 
lour compartments described above (1 ). 
Traditional methods use the determination of total body water, total body potassium, 
urinary creatinine excretion, densitometry and anthropometry. 
Recent and newer methods include neutron activation analysis, measurement of 
muscle metabolites (plasma creatinine or urinary 3 methyl-histidine), single or dual 
photon absorptiometry, bioelectrical impedance, computerized tomography and 
magnetic resonance imaging. 
In the following only those methods used in Chapter 5 and 6 are described in some 
detail. These, as well as the other methods have been extensively reviewed in ref 1 
and 2. 
Total body water 
Total body water (TBW) was found to be a relatively fixed fraction (73.2%) ofLBM (3). 
TBW can be determined by isotope dilution using isotopes of hydrogen, tritium or 
deuterium (4,5). Prerequisites of this technique are that the isotope a) has the same 
distribution volume as water, b) is exchanged by the body similar to water and c) is 
not toxic in the amounts used. Deuterium has the advantage of being relatively cheap 
and easy to determine with infrared absorptiometry, while it is not radioactive. After an 
equilibration period (two hours) has passed after the oral administration of a fixed 
amount of deuteriated water, serum is sampled for the determination of deuterium 
concentration. Thereafter TBW can be calculated: a correction should be made for 
urinary loss of deuterium and lor the exchange of deuterium with nonaqueous 
hydrogen (6). 
An important problem of the isotope dilution method as a way of determining body 
composition in patients is the assumption that TBW is 73.2% of LBM, which may be 
incorrect in edematous or dehydrated states. 
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In a similar fashion, using "'Na as the isotope, extra-cellular water or mass (ECM) can 
be determined after an equilibration period of 24 hours after the iv administration of 8 
uCi "'Na, as described in more detail by Shizgal (7). When both isotope dilution 
methods are used simultaneously the metabolically active body cell mass (BCM) can 
be calculated by subtracting ECM from LBM. 
Densitomel!y 
Based on the assumptions concerning the dens~ies of the fat and fat free masses 
described at the beginning of this chapter, it is possible to calculate the fat mass of 
the body from ~density (specific gravity), using a formula from Siri (8). Body density 
can be determined by underwater weighing, according to the Archimedes principle 
(9, 10). A correction for residual lung volume must be made, which can be 
determined w~h a helium dilution method, while another problem with this method is 
the assumption that the dens~ of the lean body mass is 1.100 gjml, which may be 
incorrect as lean body mass is a mixture of several components (unlike fat which is 
homogeneous) with densities varying from 3.00 (bone) to 0.993 (water). 
Bioelectrical impedance 
The bioelectrical impedance measurement (with a portable tetrapolar impedance 
plethysmograph which introduces a painless signal (50 kHz, 800 uA) to the body of 
the supine subject) is a swift, noninvasive and relatively new method to assess fat free 
mass, which requires little effort from subject or researcher. Results have been 
validated against more cumbersome, traditional methods of body composition 
assessment (11,12,13,14). The principle of this method lies in the induction 
of an impedance by an applied, low level alternating, electrical current in the human 
body. As the impedance at a given signal frequency is related to conductor length and 
volume, the volume of the conducting mass can be calculated from measured 
impedance and height. In living organisms the conducting mass consists of fat free 
mass as this (as opposed to the fat mass) contains virtually all the water and 
conducting electrolytes within the body. 
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1.7. SCOPE OF THE THESIS 
Wrth the development of recombinant DNA technology a practically limitless amount 
of GH became available for clinical use. 
Against the background of the sizable literature, aims of the work in this thesis were 
to further investigate: 
a) optimal dose regimens regarding beneficial and harmful effects of the 
administration of pharmacological doses of GH in catabolic elderly adults. 
b) the possible role of GH as a stimulator of cancer growth or in the treatment of 
cancer induced cachexia in a tumor-bearing rat model. 
c) body compos~ion of GH deficient adults. 
d) the effects of chronic GH replacement in GH deficient adults. 
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SUMMARY 
The effects of human growth hormone (GH) administration in elderly adults with recent 
weight loss were investigated in a metabolic ward study. Four patients were studied 
for 20 days. In addition to a constant caloric and nitrogen sufficient diet, consisting of 
the recommended amounts of protein and energy plus 20%, the patients received GH 
in dosages of 25 and 50 ug/kgjday for two four day periods (days 5-8 and 13-16, 
respectively). Significant increases in nitrogen (N) retention of 1.6 (114.2) and 1.4 
gjday (100 mmoljd), respectively, occurred when compared with the control periods. 
No difference was found between the two GH dosages but the nitrogen-retaining effect 
of the higher dose appeared to last for several days after its administration was 
stopped. Plasma IGF-1 levels rose during both treatment periods. No important 
disturbances in carbohydrate metabolism occurred. Body weight increased 2.3 kg 
during each treatment period probably due to water retention. We conclude that even 
during more than adequate nutritional intake low GH doses cause considerable 
nitrogen retention in underweight adults. 
INTRODUCTION 
Human growth hormone (GH) has anabolic effects in surgical and burn patients (1-5). 
In normal subjects (6), GH-deficient adults (7,8) and patients recovering from 
gastrointestinal surgery (9), daily administration of 100-140 ug GH/kg body weight 
combined with a normal (6) or an energy-restricted (6,9) diet resulted in a positive 
nitrogen balance. However, several adverse effects which might prevent long-term (eg 
weeks) GH administration were noted. In particular raised blood glucose and insulin 
levels (6,9), as well as fluid and sodium retention (6), were reported. In this study we 
investigated whether administration of much lower dosages of GH to underweight 
elderly adults given optimal nutritional support induces nitrogen retention without 
important changes in carbohydrate tolerance and fluid balance. 
MATERIALS AND METHODS 
Subjects 
Two men (age 59 and 70 years) and two women (age 51 and 80) were studied. All 
required enteral nutritional support for weight loss of approximately 5 kg in recent 
weeks to months, brought about by nonmalignant illness. Their serum albumin levels 
were normal, no triceps skinfold thickness measurements were performed. These 
patients had no evidence of malignant, renal or hepatic disease, or diabetes mellitus. 
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One patient (no 3) had partial hypopituitarism for which he was receiving cortisone. We 
suspect he had also growth hormone deficiency, in this respect differing from the other 
patients. The aims and methods of the study were explained and informed consent 
was obtained before the study, which was approved by the Medical Ethics Committee 
of the University Hospital Dykzigt-Rotterdam. 
Protocol 
The patients were admitted to the Metabolic Ward for a period of 24 days. During the 
entire study period they were given (enterally) a mixed diet containing 120% or more 
of the recommended amounts of energy (1 0) and protein (11) for a person of their 
age, height and weight. The diets were prepared in accordance with the wishes of the 
patients, weighed and frozen prior to admission. The patient's own accounts and 
visual confirmation by the Ward staff were used to check completeness of food intake. 
Two diets were diluted with distilled water and homogenized for measurements of their 
nitrogen and mineral content. 
The first three days after admission were used to achieve metabolic balance (these 
days are not included in the figures, the fourth day was day 1 of the study). From day 
5 through day 8 the patients received, in addition to their diet, 25 ug GH/kg body 
weight/day scat 0900 h (Period 2) and from day 13 through 16 50 ug GH/kgjday 
(Period 4). HGH (Humatrop) was supplied by Eli Lilly (Indianapolis, IN). 
The following measurements were done daily at 0800 h: weight, temperature, blood 
pressure and pulse rate. On days 1 ,4,9, 12,17 and 20 routine hematological and clinical 
chemical parameters were determined, as were blood glucose and plasma insulin 
levels before and 30,60,90, 120,150 and 180 minutes after the standardized breakfast. 
On the days the patients received GH blood glucose levels were measured fasting and 
also at 2200 hours. Plasma IGF-1 (Somatomedin-C) levels were determined at least ten 
times during the study. 
All urine was collected in 24 hour samples. In each sample nitrogen (N), creatinine, 
sodium (Na), potassium (K), calcium (Ca), phosphorus (P), and glucose was 
measured quantitatively and ketone bodies qualitatively. Faeces was collected in 4 day 
periods from day 1 onwards. The 4 day periods were demarcated by the 
administration of 500 mg carmine red, while the faeces volume was checked by the 
daily administration of 1200 mg polyethyleneglycol (PEG). Faecal N, Na, K, Ca and P 
was measured in each pooled 4 day collection. 
Methods 
Routine methods were used for the hematological and chemical measurements in 
blood. Urinary, faecal and dietary N was determined with the use of an automatic 
nitrogen analyzer, type 1400 Carlo Erba (Milan). The electrolytes were determined by 
flame photometry. Faecal PEG was measured by a turbimetric method. Nitrogen 
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balance was calculated by subtracting urinary, faecal and integumental N excretion 
from the dietary intake. Integumental N loss was estimated to be 0.5 gjday (12). 
Results are shown as grams or mmol (amino-) N, not N2. Insulin levels were 
determined by RIA in EDTA plasma using kits obtained from the lncstar Corporation 
(Stillwater, Mn ,U.S.A.). Normal fasting levels were found to be less than 20 mUjml. 
The intra-assay cvwas4.2% and the inter-assay cv 10.0%. IGF-1 was measured by RIA 
in EDTA plasma using kits obtained from the Nichol's Institute of Diagnostics (San 
Juan Capristano, CA ,U.S.A.) (13). Normal values were 0.34-1.90 Ujml in men and 
0.45-2.2 U/ml in women. The intra-assay cv was 7.2% and the inter-assay cv was 
12.8%. The statistical significance of the differences between mean values was 
determined using analysis of variance (AN OVA). When significant overall effects were 
obtained by ANOVA, multiple comparisons were made with the Newman-Keuls test. 
All data are shown as the mean +I- SE. P values < 0.05 were considered significant. 
RESULTS 
GH was well tolerated by all four patients. No changes in kidney or liver function tests, 
in electrolytes, cholesterol, triglycerides, total protein and albumin, or in leucocyte 
count were found. 
A significant increase in nitrogen retention occurred during both GH administration 
periods in all four patients. This increase was of similar magnitude with both dosages 
used. However no decrease in nitrogen retention occurred in period 5, indicating a 
prolonged effect of the higher GH dosage (Fig 1; upper panel). An example of the 
effect of GH administration on nitrogen balance in an individual patient (no 3) is shown 
in Fig 1, lower panel. 
Plasma IGF-1 levels rose during both GH treatment periods from (sub)normal values 
to high/normal values, and the values tended to be higher in period 4 than in period 
2. The plasma IGF-1 levels in all 4 patients is shown in Fig 2. 
Body weight increased during both treatment periods and then decreased within days 
after cessation of GH (Fig 2). The mean maximal increase in body weight was 2.3 + /-
0.6 kg, with a variation between 1 and 4 kg. Temporary fiuid retention was most likely 
the main cause of the weight increase, even though no peripheral edema was evident 
at any time during this investigation. 
No significant changes in sodium balance occurred during GH treatment, because of 
large individual fluctuation. Significant sodium retention occurred in patients 1, 3 and 
4 in comparison with the previous control period (p <0.05 in all instances; data not 
shown). 
Low dose GH administration caused no significant potassium retention (7, 6, 2 and -3 
mmol/d. respectively, in patients 1 to 4). In period 4, at 50 ug hGH/kgjd, significant 
retention occurred in all 4 patients (26, 16, 14 and 9 mmoljd, p<0.01 versus period 
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Figure 1: Upper panel: mean ( + j- SE) net nitrogen balance of the four patients during 
the five treatment periods.(* = p<0.01, N.S.= not significant) Lower panel: nitrogen 
balance in patient 3. The daily N intake in this patient was 12.8 g. Integumental N loss 
was estimated to be 0.5 gjday. Dotted area: average daily fecal N loss in each four 
day period. Vertical open bars: daily urinary N loss. To convert to mmoljday multiply 
by 71.4. 
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Figure 2: Left panel: Sex, age (years), length (em) and body weights (kg) and ,right 
panel, plasma Sm-C (IGF-1) levels measured in four patients treated with GH during 
a 20 day study period. (normal adult plasma Sm-C (IGF-1): 0.3-2.2 U/ml). 
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3). Significant phosphorus retention and/or decreased excretion occurred during GH 
administration, at both dosages. This retention diminished abruptly after cessation of 
the lower but not after cessation of the higher GH dosage (See Fig 3 for group means 
and as an example the balance of patient 2). Calcium balance was negative during the 
entire study period in all four patients and tended to become more negative during GH 
administration although group means did not reach significance (data not shown). 
In all patients fasting blood glucose levels remained normal ( < 6.0 mmoljl). At 2200 
h glucose levels were normal or slightly elevated to a maximum of 5.9 mmoljl on day 
6 in patient 1, 6.5 mmol/1 on day 14 in patient 2, 7.2 mmoljl on day 15 in patient 3, 
and 10.7 mmoljl on day 15 in patient 4. Post-breakfast plasma insulin levels did not 
change during the study. One patient (no 3) had slight glucosuria twice before GH was 
given (17 mmol/24h on day 3 and 4) and twice in period 2 (90 mmolj24h on day 7 
and 28 mmolj24h on day 8). Since no glucosuria occurred during period 4 we 
consider the glucosuria not to be hGH-related. No patient developed ketonuria. 
DISCUSSION 
Plasma GH and IGF-IIevels decrease with age (14,15). Elderly adults with weight loss 
due to illness or surgery might therefore benefit from the anabolic effects of 
exogenously administered GH. This study was undertaken to determine if low dosages 
of GH stimulated nitrogen retention without harmful side effects on carbohydrate and 
fluid regulation. 
We found that a low dose (25 ugjkg/d) of GH induced a significant increase in 
nitrogen retention (from 1.2 gjd (85.7 mmoljd) during period 1 to 2.8 g/d (199.9 
mmoljd) during period 2) in elderly patients with recent weight loss despite the fact 
that they received an optimal diet + 20%. Interestingly, a higher dose of 50 ugjkg/d 
of GH did not exert a more pronounced effect on nitrogen retention, (which increased 
from 1.6 gjd (114.2 mmoljd) in period 3 to 3.0 g/d (214.2 mmoljd) in period 4), 
although at this dosage a prolonged effect on nitrogen retention appeared to occur. 
Ward et al, using 100 ug GH/kg/d for 6 days in postoperative patients receiving only 
400 kcaljday, found a decrease in cumulative nitrogen excretion from 42.7 + j- 3.1 in 
the control group to 31.5 + j- 2.4 g nitrogen in the treated group, indicating an 
average nitrogen retention of 1.9 gjd (135.7 mmoljd) (9). Manson et al gave normal 
subjects eating a low caloric diet with adequate amounts of nitrogen 10 mgjday or 
approximately 140 ug GH/kgjd, for 7 days. In these individuals about 3.8 gjd (271.3 
mmoljd) nitrogen was retained (6). It should be noted that in our study, as opposed 
to those other studies, the patients received a more than adequate diet and yet, 
despite the sufficient nitrogen and caloric intake, low dose GH had a marked effect. 
An increase in nitrogen retention of 1.6 gjd (114.2 mmoljd) accounts for 
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Figure 3: Upper panel: Mean ( + /- SE) net phosphorus balance of the four patients 
during the five treatment periods.(* ; p<0.01, N.S.= not significant). Lower panel: 
Phosphorus balance in patient 2. Daily P intake 30 mmol. Dotted area: average fecal 
loss in each 4 day period, vertical bars: daily urinary loss. 
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approximately 10 g protein, which represents about 50 grams of muscle (16). 
Concerning the possible adverse side effects of high dose GH on glucose metabolism 
and water retention, fasting glucose levels did not increase, nor did blood glucose or 
plasma insulin levels change after normal breakfast. Only late in the evening (2200 h) 
did slight hyperglycemia occur in one patient, without the occurrence of glucosuria. 
However, even at these low GH dosages, sudden weight changes did occur, which 
were probably caused by water retention. Consistent sodium retention did not occur 
at the low GH dose, the higher dose caused sodium retention in 3 patients. Earlier 
workers demonstrated sodium-retaining effects of GH in rats (17, 18) and in man (4, 19-
21), whereas others found opposite resuits in rats (22,23), dogs (24) and humans 
(5,23). More recently water retention was reported during administration of biosynthetic 
methionyl-hGH to normal subjects (6). GH stimulates Na-K ATPase activity in several 
tissues including the kidney (25). Therefore direct stimulation of tubular reabsorption 
of sodium is possible. In accordance with the reports of others (17,19,20), potassium 
and phosphorus retention increased during GH treatment. On average the increases 
in potassium and phosphorus retention were proportional to the increase in nitrogen 
retention, which might indicate that both were used for muscle protein synthesis 
(muscle contains approximately 3 mmol potassium and 2 mmol phosphorus per gram 
nitrogen, (16)). 
GH administration increased plasma IGF-1 levels, as reported in several studies 
(9,26,27). Even the GH dosage of 50 ugjkgjday raised plasma IGF-1 levels to the 
upper limit of normal. At 25 ugjkgjday the IGF-1 response was smaller in two patients, 
the cause of which is unknown. We cannot draw conclusions concerning the question 
whether nitrogen retention is a direct effect of GH itself or whether it is mediated by 
IGF-1. The anabolic effect appears to last for several days after cessation of GH 
administration. Therefore it might be possible to decrease the GH dosage even further, 
or to administer GH every two or three days rather then daily, thereby decreasing the 
frequency and magnitude of adverse effects, while retaining the anabolic effects. 
Indeed Clemmons et al found that alternate day GH treatment does promote nitrogen 
retention in obese adults (28). 
In conclusion, even with a more than adequate nutritional intake, relatively low 
amounts of GH cause considerable nitrogen retention in underweight adults, and the 
nitrogen retaining effect appears to last for several days after GH administration was 
discontinued. Other treatment regimens using even lower dosages of GH or alternate 
day administration should be investigated in order to determine if they can promote 
nitrogen retention with fewer side effects. 
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SUMMARY 
In a previous study we showed that the administration of 25 and 50 ug/kg/day of 
growth hormone (GH) induced a similar anabolic effect in elderly men with recent 
weight loss, if GH administration was accompanied by optimal enteral feeding. In the 
present study we compared the effect of two GH dosages, 12.5 and 25 ug/kgjday for 
lour days on nitrogen balance. The results show that GH administration in a dose of 
25 ugjkg/day is the lowest dose in these four patients which induces nitrogen 
retention and that this dose did not induce carbohydrate intolerance or significantly 
increased insulin levels. 
GH in a dose of 25 ugjkgjday in combination with optimal enteral feeding appears the 
optimal dose to induce nitrogen retention in adults. 
INTRODUCTION 
Several reports in the sixties and seventies indicated possible beneficial effects of 
human GH administration in adult surgical and burn patients (1-5). The availability of 
synthetic GH was followed by renewed interest about the possible clinical use as an 
anabolic agent, in surgical (6,7), obese (8-10), and prednisone treated (11) patients, 
as well as in elderly adults with malnutrition and chronic obstructive pulmonary disease 
(12), andjor recent weight loss (13). Several, possibly dose-related, adverse side 
effects have been noted, in particular raised blood glucose and insulin levels (6-10), 
as well as fluid retention (6,9,10). In these studies GH was administered daily 
(6,7,10,11) or every other day (8,9) in a dosage of 100-140 ug GH/kg to patients on 
normal or energy restricted diets, but in recent studies also a lower amount of 30 
ugjkg GH per day or every other day was used (12,14). Our previous work indicated 
that GH in a dosage as low as 25 ugjkg in combination with optimal enteral nutrition 
(120% of the recommended daily amounts of protein and energy) induces similar 
nitrogen (N) retention, when compared with the previous high-dose GH studies, 
without significant disturbances in carbohydrate metabolism (13). In a recent study by 
Marcus et al (15) GH in a dose of 30 ugjkgjday was shown to have a significant N 
retaining (measured as a decrease in urinary N excretion) effect which was smaller 
than theN retention induced by 120 ug GH/kgjday, when administered for 7 days to 
healthy elderly people. At the lower GH dose no changes in glucose but an increase 
in insulin levels were observed, while at the higher GH dose both glucose and insulin 
levels increased significantly. 
In order to further investigate the lowest effective dose of GH we compared the effects 
on N balance of 12.5 vs 25 ug GH/kgjday in combination with an optimal enteral diet, 
in four adults with a non-malignant illness. 
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SUBJECTS AND METHODS 
Subjects 
Two men (aged 71 and 54) and two women (aged 50 and 63) were studied. They 
required enteral nutritional support for chronic or recent weight loss of 2-30 kg in 
recent months, brought about by non-malignant illness. These patients had no 
evidence of malignant, renal or hepatic disease or diabetes mellitus. 
Body mass index was considerably lowered in two and low normal in the other two 
patients. Their serum albumin levels were normal. The aims and methods of the study 
were explained to the patients and informed consent was obtained before the study, 
which was approved by the Medical Ethics Committee of the University Hospital 
Dijkzigt-Rotterdam. 
Protocol 
The patients were admitted to the Metabolic Ward for a period of 24 days. During the 
entire study period they were given (enterally) a mixed diet containing 120% of the 
recommended amounts of protein (16) and energy (17) for a person of their age, 
height and weight. The individual diets were prepared in accordance with the wishes 
of the patients and were weighed and frozen before admission of the patients to the 
hospital. The patients own accounts and visual confirmation by the ward staff were 
used to check completeness of food intake. Two diets were diluted with distilled water 
and homogenized for measurements of nitrogen (N) and Na contents. 
The first three days after admission were used to achieve metabolic balance (these 
days are not included in the figures, the fourth day was day 1 of the study). From day 
5 till 8 the patients received in addition to their diet, 12.5 ug GH/kg BW/day, s.c. at 
09.00 h (period 2) and from day 13 till 16 25 ug GH/kg/d. GH (Humatrop) was 
supplied by Eli Ully Co (Indianapolis, IN). 
The following measurements were made daily at 0800 h: weight, blood pressure and 
pulse rate. On days 1, 4, 9, 12, 17 and 20 routine hematological and clinical chemical 
parameters were determined, as were blood glucose and plasma insulin levels before 
and 30,60,90,120,150 and 180 min after standardized breakfast. 
Every day plasma insulin-like growth factor-\ (IGF-1) was measured as were blood 
glucose levels fasting and at 2200 h. 
All urine was collected in 24-h samples. In each sample N, creatinine, Na and glucose 
were measured quantitatively and ketone bodies were measured qualitatively. Feces 
was collected in 4-day periods from day 1 onward. The 4 day-periods were 
demarcated by the administration of 500 mg carmine red, while the feces volume was 
checked by the daily administration of 1200 mg polyethylene glycol. Fecal N and Na 
were measured in each pooled 4-day collection. 
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Methods 
Routine methods were used for the hematological and chemical measurements in 
blood. Urinary, fecal and dietary N levels were determined with the use of an automatic 
nitrogen analyzer (type 1400, Carlo Erba, Milan, Italy). The electrolytes were 
determined by fiame photometry. Feca polyethylene glycol was measured by a 
turbimetric method. N balance was calculated by subtracting urinary, fecal and 
integumental N excretion from the dietary intake. Integumental N loss was estimated 
to be 0.5 gfday (18). Insulin levels were determined by RIA in EDTA plasma using kits 
from lncstar Corp (Stillwater, MN). The intraasay coefficient of variation (cv) was 4.2%, 
the interassay cv was 10%. IGF-1 was measured by RIA in EDTA plasma using kits 
obtained from the Nichol's Institute of Diagnostics (San Juan Capristano, CA) (19). 
Normal values were 0.34-1.9 U /ml in men and 0.45-2.2 U fml in women. The intraassay 
cv was 7.2"/0 and the interassay cv was 12.8%. The statistical significance of the 
differences between mean values was determined using analysis of variance. When 
significant overall effects were obtained by analysis of variance, multiple comparisons 
were made with the Newman-Keuls test. P<0.05 was considered significant. 
RESULTS 
GH was well tolerated by all four patients. No changes in kidney or liver function tests, 
electrolytes, cholesterol, triglycerides, total protein, albumin or leucocyte count 
occurred during the study period. 
The effects of GH administration on body weight and plasma IGF-1 levels in the four 
patients are depicted in Figure 1. Weight changes during both GH treatment periods 
were minimal in 3 patients (Fig 1, left panel). In patient 3 a GH-induced (and partially 
reversible) weight gain occurred which might be attributed to fiuid retention. In this 
patient no oedema was found at physical examination, however. Sodium balance 
showed a tendency for increased sodium retention during both treatment periods in 
all patients, though the changes did not reach significance (data not shown). Plasma 
IGF-1 levels remained unchanged in patient 1. In patient 2 !GF-1 levels increased slightly 
during GH treatment, while in patients 3 and 4 a more marked increase in IGF-1 levels 
was observed, which was highest during the second period of (higher) GH 
administration (Fig 1, right panel). 
Figure 2 shows the effect of GH administration on nitrogen balance: for the group as 
a whole significant nitrogen retention occurred only at the higher GH dose of 25 
ugfkg/day. 
During both GH treatment periods blood glucose levels measured after standardized 
breakfast remained unchanged in all patients, while insulin levels showed a tendency 
to increase, not reaching statistical significance (data not shown). However, in patient 
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Figure 1: Left panel: Body weights (kg) and, right panel: plasma IGF-IIevels measured 
in four patients treated with GH during a 20 day study period. (Normal IGF-1: 0,3-2.2 
Ujml). 
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Period 2 3 4 5 
GH GH 
12. 5 ug/kg/d 25 ug/kg/d 
Patient 
-0.45 1. 64 1. 70 2. 72 1. 72 
2 -0.58 0. 23 -0. 18 1. 40 0. 66 
3 2. 16 2. 94 3.87 7. 06 1. 7 7 
4 -0.70 -0.64 -1.0 7 -0.0 6 -1.09 
Me .an 0. 11 l. 04 1. 08 2.78'* 0. 7 7 
SEH 0. 99 0.90 0.86 I. 20 0. 2 6 
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Figure 2: Nitrogen balance in the individual patients and mean ± SEM in each 
treatment period. Each period consists of 4 days. GH dose in period 2: 12.5 ugjkgjd, 
in period 4: 25 ugjkgjd. Periods 1, 3 and 5: control periods. •: p<0.05 
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3 and 4 both GH treatment periods induced carbohydrate intolerance with blood 
glucose levels at 22.00 h of7.9 and 8.6 mmoljl on day 8 and 8.4 and 8.3 mmol/1 on 
day 16, respectively. No patient developed glucosuria or ketonuria. 
DISCUSSION 
GH treatment in adults with (recent) catabolism has been shown to reduce 
catabolism/induce anabolism. However the optimal dosage of GH which induces these 
positive effects without adverse side effects (and at reasonable cost) has not been 
established. In our previous report (13) we demonstrated that 25 ug GHjkg/d was 
equipotent to 50 ugjkgjd in its power to induce nitrogen retention, while this low dose 
had fewer side effects. The results from the present study show that a further 
decreased GH dosage (to 12.5 ugjkg/d) does not result in a significant nitrogen 
retention any more. In agreement with our previous results we observed a pronounced 
interindividual variation in the reaction of body weight and IGF-1 levels to GH 
administration. In contrast to our previous results we observed in two of the present 
patients at the GH dosage of 25 ugjkg/d the induction of an, albeit minor, glucose 
intolerance. One patient had a marked increase in weight, without the development of 
overt oedema. Disappointingly even the lowest GH dose tended to induce sodium 
retention during this short-term study. 
In contrast to our short term study in adults with optimal enteral nutrition, a report by 
Snyder et al (1 0) showed that the anabolic effect of growth hormone in obese diet-
restricted subjects was optimal when a dosage of 100 ugjkg/d was used. However 
this dose caused fluid retention amounting to about 2.5 kg, as well as significant 
disturbances in carbohydrate metabolism, even in severe diet restricted subjects. 
In conclusion we show that in adult patients given more than adequate enteral feeding 
(120% of the recommended daily requirements of calories and protein), 25 ug 
GHjkgjday is the lowest dose which induces anabolism as measured by the nitrogen 
balance technique. In our previous study we showed that the nitrogen retaining effects 
of25 and 50 ug GH/kgjday were similar. This suggests that a daily dose of 25 ugjkg 
of GH is the optimal dose to induce anabolism in patients during optimal enteral 
nutrition, with the least adverse effects on carbohydrate and fiuid homeostasis. It has 
to be stressed, however, that the considerable interindividual variation in the response 
to GH administration noted in our study, as well as the fact that only lour patients were 
investigated limits the value of our conclusions, making them preliminary. 
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CHAPTER 3 
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SUMMARY 
The direct effects of human GH and IGF-1 on PRL secretion and cell proliferation were 
studied on PRL secreting rat pituitary tumor 7315b cells in vitro. as well as the effects 
in vivo of human GH administration on body weight, IGF-1 levels and tumor size in rats 
bearing this transplantable tumor. In the in vitro studies IGF-1 levels above 5 nM 
stimulated PRL release in a dose-dependent manner while GH, in concentrations of 
0.23-45 nM, did not affect PRL release. Cell proliferation was stimulated by IGF-1 in a 
dose dependent manner from 0.5 nM onwards, while GH did not have an effect. The 
in vivo studies showed that 1 mg GHjratjday reversed tumor-induced cachexia and 
normalized the suppressed IGF-1 levels without stimulating tumor growth. It is 
concluded that tumor-induced cachexia can be prevented or reversed by exogenous 
GH administration without an increase in tumor mass, even if a tumor model is used 
whose cultured tumor cells respond to exposure to IGF-1 with a mitotic response. 
INTRODUCTION 
In animals ,as well as in man, growth hormone (GH) exerts a wide variety of effects. 
Most of its growth-promoting actions are mediated via the formation of Insulin-like 
Growth Factor I (IGF-1), while it also exerts a direct lipolytic action (1 ). Knowledge 
about the effects and possible therapeutic uses of GH in adults has been limited by 
the lack of available supplies. Therefore during the past decades its use has mainly 
been restricted to the treatment of children with short stature. 
After human GH, which is identical and bioequivalent to endogenous GH, has been 
produced by recombinant DNA technology, new reports concerning the usefulness of 
GH therapy in adults with various catabolic disorders (trauma, surgery) have been 
published (2-5). To date no studies have been carried out on the potential beneficial 
anabolic effects of GH therapy in cancer patients. 
Cancer-induced cachexia diminishes the quality of live significantly and may be 
attenuated by GH therapy. The amount of weight Joss in cancer patients is positively 
correlated with the overall mortality. In addition improvement of nutritional status may 
reduce chemotherapy related toxicity, as has recently been shown in a rat model (6). 
The usefulness of (par)enteral (hyper)alimentation in the management of cancer 
patients is controversial (7-10). 
Controversy exists also concerning the possible carcinogenic andjor tumor growth-
stimulating effects of GH treatment in humans with GH deficiency, either direct or 
mediated by circulating or locally produced IGF-1 (11-13). According to some 
investigators the incidence of neoplasms in acromegaly is increased (14-17), though 
others did not observe this relation (18-19) 
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In the present study we investigated the direct effects of human GH and IGF-1 on 
Prolactin (PRL) secreting rat pituitary tumor 7315b cells in vitro, as well as the effects 
of human GH administration to rats bearing this transplantable rat pituitary tumor 
7315b. In the in vitro experiments the effects on cellular DNA content and PRL 
secretion were investigated, while in the in vivo experiments changes in tumor size, 
body weight, plasma IGF-1, PRL and GH levels were studied. 
METHODS 
In vitro tumor cell experiments. 
Female Buffalo rats (R.B.I., Rijswijk, the Netherlands), weighing 150-170 g, were kept 
in an artificially illuminated room (08.30-20.30 h) with food and water ad libitum. The 
animals were inoculated subcutaneously between the scapulae with a cell suspension 
of the transplantable, PRL secreting 7315b rat pituitary tumor as described in detail 
elsewhere (20). Three to four weeks after inoculation of the tumor cell suspension a 
tumor of approximately 20 cm2 has grown on the back of the animals. At this moment 
the animals were killed by an overdose of ether anaesthesia and the tumor was 
carefully removed and collected in a sterile saline solution (9 gjl NaCI). 
7315b pituitary tumor cells were isolated by mechanical dispersion. The isolated tumor 
was washed twice with calcium-, magnesium- free Hank's Balanced Salt Solution 
(HBBS) supplemented with 1% human serum albumin (HSA), penicillin (105 U/1), 
streptomycin (1 DO ugjl), fungizone (0.5 mgjl) and sodium bicarbonate (0.4 g/1 final 
concentration). The capsula of the tumor was carefully removed, after which the tumor 
was minced into small pieces. The remaining suspension of tumor tissue was gently 
vortexed for 30 seconds. After vortexing the suspension was centrifuged at 600 g for 
5 min and the pellet was washed twice with HBSS+HSA. The remaining pellet was 
resuspended in HBSS+ HSA and the suspension was filtered over a nylon gauze. In 
order to separate vital from non-vital cells the suspension was layered on Ficoll-
lsopaque (density 1.077 gjml; prepared by the Dijkzigt Hospital Pharmacy, Rotterdam, 
the Netherlands) and centrifuged at 500 g for 20 min. The interphase containing vital 
cells was collected and washed twice with HBSS+HSS. Finally, the cells were 
resuspended in culture medium. 
The culture medium used in all experiments consisted of Minimal Essential Medium 
with Earle's salts (MEM) supplemented with MEM non-essential amino acids, sodium 
pyruvate (1 mmol/1), 10% fetal calf serum, penicillin (105 U/1), streptomycin (100 ugjl), 
fungizone (0.5 mgjl), l-glutamine (2 mmoljl) and sodium bicarbonate (2.2 gjl final 
concentration). The medium was adjusted to pH 7.4 with 1 moljl NaOH. The 7315b 
pituitary tumor cells were seeded at a density of 20.000 cells per well in 1 ml of culture 
medium in 24 well plates (Costar, Cambridge, Mass, USA) without or with IGF-1 or GH. 
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After 6 days of culture the media and cells were collected and stored at -20 C until 
analysis. Medium and supplements were purchased from Grand Island Biological Co. 
Europe (Paisly, Scotland). IGF-1 was obtained from Sachem (Sachem Feinchemicalien 
ASG, Bubendorf, Switzerland) and human recombinant growth hormone (GH, 
Humatrope) from Eli Lilly & Co, Indianapolis. 
Rat PRL concentrations in the culture media were measured by a double antibody RIA 
using materials and protocols supplied by the distribution officer of the NIADDK. All 
results are expressed in rat prolactin reference preparation-1 (RP-1). 
The DNA content of the tumor cells was determined as described in detail elsewhere 
(21). The method is based on a DNA dependent fluorescence enhancement of a 
fluorochrome. In short, cultured tumor cells, which did not attach to the floor of the 
wells, were collected at the end of the incubation period and washed twice with an ice-
cold saline solution. The remaining cell pellet was stored at -20 C until analysis. The 
cells were extracted with 300 uL ammonia solution (1 moljl) + Triton x 100 (0.2"1<> v jv) 
by sanification during 5 seconds at amplitude 15 (Soniprep 150; MSE). Thereafter 2 
ml assay buffer (100 mmoljl NaCI, 10 mmoljl EDTA, 10 mmoljl Tris; pH 7.0) was 
added. The remaining solution was centrifuged at 2000 g during 5 min and 100 ul 
aliquots of the supernatant were mixed with 1.5 ml Hoechst dye H33258 (1 00 ngjml). 
Fluorescence was measured after 15 min with the exication and emission wavelengths 
set at 350 nmoljl and 455 nmoljl respectively. Fluorescence of experimental samples 
was referenced to a standard curve of calf thymus DNA (type II, no D-3636; Sigma 
Chemical Company, Stlouis, Mo, USA), All data are expressed as means + 1- SE. 
In vivo tumor experiments. 
In two experiments the effect of GH administration on the growth of the 7315b tumor 
and on reversal (experiment 1) or prevention (experiment 2) of tumor-induced cachexia 
was evaluated. Tumor growth was evaluated by expressing tumor size in centimetres 
squared (maximum length x maximum width) which has been shown to be closely 
correlated with tumor weight (22). In the first experiment the effects of administration 
of 1 mg GHjratjday (Humatrope, Eli Lilly & Co, Indianapolis) subcutaneously in 0.25 
ml diluent starting on day 13 after tumor implantation until the end of the experiment 
(day 23) were evaluated, while in the second experiment the effects of GH 
administration for 15 days starting on the day of inoculation were evaluated. In both 
experiments tumor bearing controls received daily injections of diluent only while in the 
second experiment the effects of either GH or diluent was evaluated in non tumor 
bearing controls as well. Each group of animals consisted of 8 rats. 
Plasma IGF-1 levels were measured in EDTA plasma obtained from the tail vein during 
the experiment or after decapitation at the end of the experiment The commercial kit 
lor the determination of IGF-1 from the Nichol's Institute of Diagnostics (San Juan 
Capistrano, CA, USA) was used. The intra-assay cv was 7.2 and the inter-assay cv 
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12.8%. PRL was determined in the same samples by double antibody RIA as 
described above. 
Statisilcaf evaluation 
Statistical analysis was done by analysis of variance, followed by Duncan's test for 
determining the differences between control and experimental groups. In the in vivo 
experiments changes in body weight were evaluated by Students unpaired t-test. 
RESULTS 
The effects of IGF-1 and GH on PRL secretion and DNA content of cultured 7315b 
tumor cells 
The 731 5b tumor cells were cultured for a period of 6 days. The effects of a wide 
concentration range of IGF-1 (0.5-50 nmoljl) and GH (0.23-45 nmoljl) were investigated 
(fig 1). Low concentrations of 0.5 and 1 nmoljl IGF-1 did not affect PRL release, while 
5,10 and 50 nmoljl IGF-1 stimulated PRL release in a dose dependent manner (5 
nmoljl vs control: p<0.01; 10 vs 5 nmoljl: p<0.05; 50 vs 10 nmoljl: p<0.05). A low 
concentration of IGF-1 (0.5 nmoljl) stimulated the DNA content of the cells after 6 days 
by 12% (p<0.05 vs control), while higher concentrations of IGF-1 stimulated the DNA 
content in a dose dependent manner, 10 nmol/1 being the maximal stimulatory 
concentration (stimulation by 1, 5, 10 and 50 nmoi/IIGF-1 being 24, 37, 50 and 55% 
respectively, 1 and 5 vs 0.5 nmoljl: p<0.05; 10 and 50 vs 1 nmoljl: p<0.01). We also 
measured the IGF-1 concentration of the culture medium used in these experiments: 
the final IGF-1 concentration of the medium to which the control cells were exposed 
amounted to 0.2 nmol/1. 
Human GH in a concentration between 0,23 and 45 nmoljl did not affect PRL release, 
while it did also not influence the DNA content of the tumor cells after 6 days of culture 
(fig 1). 
The effect of the administration of human GH in vivo on 7315b tumor growth, body and 
organ weights, serum PRL and /GF-1 levels in rats. 
The daily, subcutaneous administration of a pharmacological dose of 1 mg GH/rat per 
day for 10-15 days was investigated on 7315b tumor growth in two separate 
experiments. 
In the first experiment GH was injected daily from day 13 till 23 after tumor 
implantation. GH administration did not affect pituitary tumor growth: tumor size (as 
expressed in cm2) did not differ from that found in tumor bearing animals which 
received the diluent only (fig 2). In contrast, however, the GH treated tumor bearing 
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Figure 1: The effects of increasing concentrations of IGF-1 (upper panels) and GH 
(lower panels) on rat PRL release (ng/6 days) and DNA content (ngjwell) of 7315b 
tumor cells cultured for 6 days. 
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figure 2: The effects on body weight (left panel; g) and tumor size (right panel; cm2) 
of the administration of human GH (1 mgjratjday) or placebo for 10 days to rats 
bearing the transplantable rat pituitary tumor 7315b starting on day 13 after tumor 
implantation. N =6 for each group; mean ± SEM. 
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rats had gained weight considerably. In fig 2 ~ is shown that during the 10 day 
placebo treatment period tumor bearing control animals gained 4.5 ± 6 g (mean ± 
SEM) in weight However, the GH treated tumor bearing rats gained 24.3 ± 1 g. 
After deduction of the mean tumor weight (35.1 ± 5 g in the placebo treated and 40.5 
± 2 g in the GH treated animals; NS) the weight of the placebo treated animals 
amounted to 166 ± 6 g, indicating a mean body weight gain of only 3 ± 2 g, in 
comparison with the mean body weight prior to tumor implantation. The actual mean 
body weight of the GH treated group at the end of the experiment amounted to 180 
± 4 g (220.5 ± 5.4 minus 40.5 ± 2). Therefore the GH treated animals had gained 18 
± 2 g in weight during the 22 day investigational period. This weight gain did not differ 
from that observed in non-tumor bearing controls (starting weight 161 ± 2.8, final 
weight 175.3 ± 3.7) but was higher than that seen in the tumor bearing control rats 
(p<0.01). 
In comparison with non-tumor bearing controls plasma IGF-1 levels were slightly 
lowered on day 12 after tumor implantation (NS, table 1 ). This decrease was statistical 
significant in the tumor bearing controls 18 and 22 days after tumor implantation 
(p<0.05) , while GH treatment in tumor bearing animals resulted in a significant 
stimulation of IGF-1 to levels which were comparable w~ those observed in non-tumor 
bearing controls (both on day 18 and 22: p < 0.05 vs tumor bearing controls). 
Table 1: The effect of GH (1 mgjratjday) or placebo administration on the total 
plasma IGF-1 concentration (in nmol/1) of rats with the pituitary tumor 7315b, for ten 
days starting on day 12 after tumor implantation (mean ± SEM; n=6 per group). 
a:P<O.OS vs control non tumor; b:P<O.OS vs control tumor. 
IGF-I (nmo1/1) 
day 12 18 22 
control non tumor 25.3 +j- 1.6 23.6 +j- 1.0 27.2 +j- 2. 4 
control tumor 23.1 +j- 17.2 +/- 1.1a a 1.7 19.7 +/- 0.9b 
tumor+ GH 23.2 +j- 0.8 27.7 +j- 1. 7b 28.5 +/- 0.7 
Prolactin levels in the GH treated tumor bearing group did not differ significantly from 
the placebo treated tumor bearing animals (1133 ± 156 vs 771 ± 163 ngjml). As to 
be expected after implantation of a PRL secreting tumor, PRL levels in both tumor 
bearing groups were significantly higher compared with the non tumor bearing controls 
(81 ± 32). 
In the second experiment GH administration was started on the day of tumor 
implantation and continued for 15 days. Again no significant effect of GH administration 
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Figure 3: The effects on body weight {left panel; g) and tumor size (right panel; cm2) 
of the administration of human GH (1 mgjrat(day) or placebo lor 15 days to rats with 
or without the transplantable rat pituitary tumor 7315b implanted on day 1. N;6 for 
each group; mean .±. SEM. 
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on tumor growth was observed (fig 3). GH exerted powerful stimulatory effects on 
body growth both in the non-tumor and in the tumor bearing animals. The placebo 
treated non-tumor bearing rats gained 14 .±. 2 g in weight. while in the GH treated 
control group this amounted to 33 .±.3 g (p<0.01). The tumor bearing placebo treated 
rats gained 34 .±. 4 g in weight. but after deduction of tumor weight (26 .±. 4 g) net 
weight gain was only 8 .±. 2 g. Growth hormone administration to tumor bearing 
animals resulted in a total weight gain of 49 .±. 4 g; after deduction of tumor weight (29 
.±. 7): 20 .±. 2 g (p<0.01 vs tumor bearing-placebo treated rats). 
After 15 days of GH treatment plasma IGF-IIevels in the GH treated non-tumor bearing 
rats were significantly elevated compared with the placebo treated non-tumor bearing 
animals (p<0.05; table 2). The consequences of tumor implantation on IGF-1 levels 
again became evident: both on day 16 and 22 they were significantly suppressed in 
comparison with the placebo treated non-tumor bearing rats (p < 0.05 in both 
instances). Administration of GH to tumor bearing rats resulted already on day 9 but 
also on day 16 in a stimulation of IGF-1 levels, which were significantly higher than in 
the placebo treated tumor bearing animals (p<0.05). These levels were, both on day 
9 and 16, similar to those observed in GH treated non-tumor bearing rats, and on day 
16 also higher than in placebo treated non-tumor bearing controls (p < 0.05). On day 
22 the stimulatory effects of GH administration in the first 15 day period had ceased 
and IGF-IIevels had indeed decreased to levels comparable with those in the placebo 
treated tumor bearing group. PRL levels in the GH treated tumor bearing group again 
did not differ significantly from the placebo treated tumor bearing rats (618 .±. 195 vs 
520 .±. 103 ngjml). 
Table 2: The effect of GH (1 mgjratjday) or placebo administration on the total 
plasma IGF-1 concentration (in nmo/jl) of rats with the pituitary tumor 7315b, for 15 
days staJting on the day of tumor implantation (mean .±. SEM; n =6 per group). 
a:P<0.05 vs non tumor-placebo; b:P<0.05 vs tumor-placebo. 
IGF-I (runol/1) 
day 9 16 22 
non tumor-placebo 20.6 +/- 1.0 22.2 +/- 0.5 21.4 +/- 1.0 
+/- 0.6a a non tumor+GH 23.9 +/- 1.1 28.1 25.0 +/- 1.0 
tumor-placebo 18.3 +/- 0.7 16.9 +/- 0. sa 14.1 +/- 1.1a 
tumor+GH 23.8 +/- 1.1b 25.9 +/- 0.7b 15.8 +;- 1.1 
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PRL levels were in both tumor bearing groups were elevated compared with both non 
tumor bearing groups (35 .±. 6 in the placebo treated and 26 .±. 7 ngjml in th GH 
treated rats). 
DISCUSSION 
Evidence is accumulating that IGF-1 plays a role in tumorgenesis and tumor growth. 
In vitro investigation of several tumor cell lines demonstrate specific binding sites for 
IGF-1 (23-31), increased binding to IGF-1 receptors when compared with less 
dedifferentiated cell lines or with normal surrounding tissue (24,29-31), production of 
IGF-1 by tumor cell lines or tissue (32,33) and increased DNA synthesis and cell growth 
in response to IGF-1 (23,25,27 -29,32,34-36). 
From these observations one might derive strong arguments against the therapeutic 
use of GH to reduce catabolism andjor induce an anabolic state in patients with 
cancer-induced cachexia, since it might simultaneously stimulate growth of the cancer 
itself. In addition evidence was also presented from studies by Friesen's group that GH 
directly induces the expression of the c-myc oncogene in a lymphoma cell line (37) 
Preliminary results (J. Foekens, personal communication) from investigations into the 
presence of IGF-1 binding sites on the rat pituitary tumor cell line 7315b used in this 
study indicate indeed the presence of specific high affinity IGF-1 binding sites on this 
tumor. 
The results of the in vitro studies are in accordance with similar studies in other cancer 
cell lines, in that it was shown that IGF-1 induces cell proliferation and protein (in this 
case PRL) secretion. GH itself did not induce either effect. 
The results of the in vivo studies show that GH administration for 10 to 15 days 
reverses (first experiment) or prevents (second experiment) tumor-induced cachexia 
without stimulating tumor growth measured in cm2 or PRL secretion. On weight basis 
we used 120-240 times the GH dosage used in human studies to induce an anabolic 
state (38). 
Our results are in disagreement with the results of Svaninger et al (39), who 
demonstrated no improvement of body composition and muscle wasting (nor an 
increase in tumor growth) by GH administration in adult, non growing, sarcoma 
bearing mice, while in hypophysectomized rats GH administration stimulated body and 
tumor growth to a similar extent. In their sarcoma tumor model in intact animals GH 
levels were elevated from day 8 after tumor implantation, explained by the authors as 
a way to promote endogenous substrate mobilization. The exogenous GH dosage was 
only 100 ug/100 g BWjday (as opposed to our GH dose of 1 mgjrat, which 
corresponds to 600 ug/100 g BW/day) which was insufficient to stimulate growth in 
freely fed control mice. In their study no IGF-1 levels were reported. 
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In our study the decrease of IGF-1 levels in tumor bearing rats reflects the tumor 
induced cachexia (40-41) and was reversible by GH administration. IGF-1 levels 
decreased to the low level observed in untreated tumor bearing rats within days after 
cessation of GH administration. It might be speculated that due to tumor-produced 
cytokines Qike interleukins, tumor necrosis factor), a catabolic pathophysiologic 
condition occurs, perhaps both by a direct effect on peripheral tissues and indirectly 
by reducing GH and IGF-1 levels. Exogenous GH appears to be capable to reverse 
these tumor induced effects. 
In conclusion tumor-induced cachexia can be prevented or reversed by exogenous GH 
administration without an increase in tumor mass, even when a tumor model is used 
which contains specific binding sites for IGF-1 and the cultured tumor cells respond to 
exposure to IGF-1 with a mitotic response. 
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SUMMARY 
Body composition in a group of GH deficient adults was compared with a control 
group, matched for age, sex, body height, body weight and body mass index, using 
bioelectrical impedance and deuteriumoxide dilution methods and hydrodensitometry. 
The body fat percentages of GH deficient adults were higher in spite of comparable 
weights, heights, age and body mass index. Body impedance was higher in the GH 
deficient adults, also after correction for differences in height and fat free mass. As a 
consequence, prediction formulas lor body composition from body impedance, 
developed in normal subjects can not be applied to GH deficient subjects. The higher 
body impedance in the GH deficient subjects can be ascribed to a smaller amount of 
extracellular water in these subjects compared to the controls. 
INTRODUCTION 
At present growth hormone (GH) deficient adults (both GH deficient children who have 
reached their final height and adults who have developed GH deficiency as part of 
hypopituitarism) are not substituted with GH for two reasons. Firstly the limited supply 
of pituitary derived GH has restricted its use to children with short stature, and 
secondly GH deficient adults, if adequately substituted for other hormonal deficiencies 
(if present), have a normal life expectancy. Since recombinant DNA technology has 
increased GH availability, a more widespread use of GH has become feasible. 
Therefore the possible adverse effects of GH deficiency in adult life have become a 
matter of more than academic interest. Normally spontaneous and stimulated GH 
secretion continues into adult life, although it decreases with age (1-10). 
GH has been shown to affect cardiac function (11,12), renal perfusion (13,14), the 
immune system (15,16), metabolic homeostasis (17), and body composition (18). 
Reduced social performance in adults with GH deficiency has been reported (19,20), 
albeit not by all investigators (21). 
We report the results of an investigation of body composition by bioelectrical 
impedance analysis (BIA) and 020 dilution measurements in a group of adults with 
GH deficiency in comparison with body composition measurements by BIA and 
hydrodensitometry in a group of age, sex, height and body weight matched (healthy) 
controls. 
Patients and methods 
The study group consisted of 13 subjects who were known with isolated GH 
deficiency or (incomplete) hypopituitarism for at least 2 years (Table 1). If previously 
treated with pituitary derived GH (patients 4,7,8 and 13) this substitution treatment had 
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been stopped at least 2 years before the study. In 11 of these 13 patients (partial) 
hypopituitarism was present, which was adequately substituted. Adrenal insufficiency, 
which was present in 10 patients, was treated with either cortisone acetate (15-37.5 
mgjday, divided over 2-3 doses) or hydrocortisone (15-30 mgjday, divided over 2-3 
doses). The absence of adrenal insufficiency in patients 2,4 and 5 had been confirmed 
with a metyrapone test. Insufficiency of the pituitary-thyroid axis was present in 10 
patients, who all received substitu1ion with L-thyroxine (75-175 ug daily). This had 
resulted in normal to high-normal free thyroxine levels in all patients. The male patients 
received either 250 mg testosterone-enantate intramuscularly once every 3 weeks 
(patients 3,6,7,8) or80 mg testosterone-undecanoate 2-3 times daily (pat 1, 12, 13). The 
four female patients with hypogonadism all received cyclic estrogen; progestagen 
substitution therapy. If present adrenal, thyroid, andjor gonadal insufficiencies had 
been treated for at least 2 years with continuous, unchanged medication. All patients 
were studied on an outpatient base. Although not generally accepted, we omitted 
therefore an insulin test to prove the presence of GH deficiency. The presence of GH 
deficiency in these 13 patients was confirmed however by the presence of a basal 
plasma IGF-1 level of less than 0.5 U jml in combination with a peak GH of less than 
7.0 ug/1 after stimulation with human Growth Hormone Releasing Hormone (GHRH, 
Somatobiss, Ethifarma, The Netherlands). After an overnight fast a catheter was 
inserted into an antecubital vein and blood was sampled for basal IGF-1 and GH levels 
(t=-15 min). At t=O min, 1 ug GHRH/kg body weight was injected intravenously after 
which blood was sampled for GH determination at t= 5, 10, 20, 30, 45, 60 and 90 
minutes. IGF-1 levels were determined in EDTA plasma using the commercial RIA kit 
from the Nichols Institute of Diagnostics (San Juan Capristano, Ca, USA). Normal 
ranges (between 18 and 65 yr) are 0.34-1.90 Ujml in men and 0.45-2.20 U/ml in 
women. These are based on 95% confidence intervals for a group of more than 100 
controls. This assay has an intra- and inter-assay coefficient of variation (cv) 7.2 and 
12.8% respectively. Serum GH was measured using a commercially available IRMA 
from Eurodiagnostics (Apeldoorn, The Netherlands). The intra- and inter-assay cvwere 
10.2 and 11.1 % respectively. 
In four patients (no 4,7,6 and 13) GH deficiency had already previously been 
demonstrated by the presence of an insufficient response of GH to an insulin-induced 
hypoglycaemia as well as to arginine-infusion. 
Body composition was measured (in the study and control group) after an overnight 
fast by the tetrapolar bioelectrical impedance method as described previously (22-25) 
with a body composition analyzer (RJL-systems BIA-101 Detroit, Ml, USA). Fat-free 
mass (FFM) was calculated from bioelectrical impedance !rl and body height (H, m) 
using the equation of Deurenberg (FFM = 0.652 x 104 x H /R + 3.8 x S (S = gender: 
male=1, female=O) +10.9; (26)), or Lukaski (FFM=0.838 x 104 x H2/R +4.2; (23)). 
Additionally in the GH deficient group body composition (total body water, TBW) was 
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determined by o2o dilution as described elsewhere (27,28). In short, after an 
overnight fast and insertion of a catheter into an antecub~al vein blood was sampled 
and the patient was given, by mouth, a dose of 0.24 g 99.7% D,O/kg body weight 
diluted in 200 ml H20. After 150, 180 and 210 min 10 ml heparinized blood was 
withdrawn, and the plasma stored at -20 C until analysis. After sublimation, D,O 
concentration was measured by infrared spectrophotometry and TBW was calculated. 
A correction of 4 % was made to compensate for exchange of deuterium with non-
water compartments (29). FFM was calculated from TBW by dividing TBW by 0.73 
(30). Body compos~ion measurement by underwater weighing was not performed in 
the patients. 
The controls consisted of 23 healthy adult volunteers matched with the study group 
for age, sex, body height and weight and derived from a much larger population of 
healthy subjects. 
In the controls body composition was, apart from bioelectrical impedance, also 
measured dens~ometrically by underwater weighing (to the nearest 0.05 kg; 3826 MP 
81 Sartorius, Gottingen, Germany) with simultaneous determination ofthe residual lung 
volume by helium dilution. Siri's formula (31) was used to calculate fat mass (FM) and 
FFM from total body densey. The equipment has a precision of 1% (0.002 kg/1). 
Aims and methods of the study were explained to patients and controls and informed 
consent was obtained before the study, which was approved by the Medical Ethics 
Committee of the Universey Hospital Dijkzigt-Rotterdam and the Ethical Committee of 
the Department of Human Nutrition, University of Wageningen. 
Statistical analyses were performed with the SPSS PC-programm (1988). Analysis of 
(co-)variance techniques and Student t-tests were performed to test for differences 
between groups or lor differences in variables within groups. Regression lines were 
tested for differences in slopes andjor intercepts by the method described by 
Kleinbaum et al (32). All values are expressed as mean ± SEM. 
RESULTS 
Table 1 shows some individual characteristics of the GH deficient patients. As can be 
seen in Table 2 the patient and control groups did not differ regarding sex distribution, 
age, height, weight and body mass index (kg/m2). However percentage body fat was 
significantly higher in the group of GH-deficient patients. Also body impedance (R) was 
significantly higher in the patients (P < 0.01, see Fig 1 ), also after correcting (by 
analysis of covariance) for differences in FFM and height (data not shown). Fat free 
mass calculated with the formula's of Deurenberg (FFM-De) or Lukaski (FFM-Lu) was 
significantly lower (P < 0.05) in the patients in comparison with the controls. Similarly 
fat mass (FM) and body fat percentage in the patients was higher compared to the 
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Table 1: Patient characteristics. 
GH DEFICIENCY HORMONE 
PATIENT SEX AGE HEIGHT WEIGHT CAUSE DURATION IGF-1 PEAK GH SUBSTITUT GH DOS!$ 
yr em kg yr U/ml ug/1 C/T/G ug/kg/d 
I F 46 137 61 a 20 0.2 1.7 +/+/+ 12 
2 F 32 165 92 b 15 0.1 1.1 +/+/+ 16 
3 F 27 145 65 a 12 0.2 3 .I 6 
4 M 32 182 90 b 14 0 .I 2.3 +/+/+ 16 
5 M 34 161 47 a 11 0.3 4.2 +/+/+ 25 
6 M 25 176 94 b 12 0.2 3.2 15 
7 F 33 153 56 b II 0.2 2.9 /+/ 18 
8 F 28 164 56 b 12 0 .I 0.7 +/+/+ 25 
Mean 32 160 70 13 0.2 2.4 17 
SHl 2 5 6 I 0.0 0.4 2 
a: idiopathic GH deficiency, b: after surgery for a craniopharyngeoma. Peak GH=maximal 
GH level after the iv injection of GHRH (I ugjkg BW). C: (gluco)corticosteroids, 
T: L-thyroxine, G: gonadal steroids. Patients 2, 4 and 6 were treated with 1.48 mg 
(4 IU) of GH/day, which corresponded with a dose of 15-16 ug/kg/day. 
Table 2: Some physical characteristics for patients and controls. 
N (malesjfemales) 
Weight (kg) 
Height (m) 
Body Mass Index 
Age (years) 
Impedance (Ohm) 
*:P<0.01 
Controls 
Mean ± SEM 
23 (15/8) 
70.7 3.7 
1. 70 0.02 
24.3 0.8 
32.2 2.4 
474 14 
Patients 
Mean ± SEM 
13 (8/5) 
72.7 5.3 
1.67 0.04 
26.0 1.4 
32.6 2.9 
602 34 * 
Table 3: Impedance, fat-free mass, fat mass and fat percentage in controls and 
patients calculated with the formula's of Lukaski (23) or Deurenberg (26). 
Controls Patients P value 
Mean ± SEM Mean ± SEM 
Impedance (Ohm) 474 14 602 34 <0.001 
FFM-LU (kg) 56.5 2.3 45.4 3.7 <0.05 
FM-Lu (kg) 14.2 1.7 27.3 2.4 <0.001 
Fat Percentage-Lu (%) : 19.3 1.6 37.6 2.2 <0.001 
FFM-De (kg) 54.1 2.1 45.3 3.2 <0.05 
FM-De (kg) 16.6 1.8 27.4 2.8 <0.01 
Fat Percentage-De (%) : 22.6 1.5 37.1 2.3 <0.001 
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Figure 1: Impedance (Ohm) in the individual controls and patients as well as mean .±. 
SEM for both groups. 
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controls (Table 3). 
In the GH deficient patients FFM calculated from total body water was markedly lower 
than FFM derived from hydrodensitometry in the control subjects, but the difference 
did not reach statistical significance (P = 0.20). However, the fat mass (FM) and the 
body fat percentage were significantly higher in the GH deficient patients compared 
with the control subjects (P= 0.012 and P= 0.001 respectively; Table 4). 
Table 4: Fat-free mass, fat mass and fat percentage calculated from the body density 
in the controls and from total body water in the patients. 
Controls Patients P value 
Mean ± SEM Mean ± SEM 
Fat-free Mass (kg) 52.4 2.3 46.6 3.9 NS 
Fat Mass (kg) 18.4 1.8 26.2 2.3 <0.01 
Fat Percentage (%) 25.3 1.6 36.2 2.3 <0.001 
In the controls FFM determined densitometrically was lower than the FFM calculated 
from body impedance, whereas in the patients no differences were observed between 
predicted FFM by impedance and FFM as determined by deuterium oxide dilution 
(Table 5). 
Table 5: Comparison between fat free mass calculated from densitometry in the 
controls and deuteriumoxide dilution in the patients (FFM) with the fat free mass 
calculated from impedance with the formula's of Lukaski (FFM-Lu) and Deurenberg 
(FFM-De). 
Controls 
Patients 
FFM 
52.4 ± 2.3 
46.6 ± 3.9 
*:P<O~Ol compared to FFM 
FFM-Lu 
56.5 ± 2.3 
45.4 ± 3.7 
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FFM-De 
54.1 ± 2.1 
45.3 ± 3-2 
fat free mass ( kg) 
80 
60 
40 
20 
0 20 40 
o patients: FFM ;; 0.817 • H2/R + 6.3 
x controls: FFM::: 0.817111 H2/R + 1.3 
60 80 100 
(body height J2 /impedance (cm2/QJ 
Figure 2: Regression between impedance (H2 fR) and FFM (densitometry) in the 
controls and FFM (Deuteriumoxide dilution) in the patients. The slopes of the two 
regression equations are not significantly different (P;Q.15), but the intercept in the 
patients is significant higher (P;Q.0001). 
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Fig 2 shows the relation between body impedance (expressed as H'/R) and FFM 
(determined by way of underwater weighing) in the individual controls and the relation 
between impedance and FFM (determined by way of deuterium dilution) in the 
individual patients. The calculated prediction formula's, for controls and patients, lor 
FFM from impedance are different the slope of the regression line is similar (P;0.15) 
but the intercept in the patients is higher (P;0.0001). 
DISCUSSION 
Reported differences in body composition in GH deficiency mainly concern children 
in whom higher skinfold thicknesses and lower muscle masses or muscle widths have 
been found. These changes are at least partially reversible after GH treatment (33-38). 
After cessation of GH treatment fat mass has been shown to increase and muscle 
mass to decrease (33,34,38). 
In this study we investigated 13 adult patients with GH deficiency. In 11 of them 
(partial) hypopituitarism was present, which had been substituted already adequately 
in all instances for more than 2 years. We confirmed the presence of GH deficiency 
in these patients by the combination of a low peak serum GH level after stimulation of 
the pituitary by GHRH together with the low circulating IGF-1 level (which in these 
patients was not caused by malnutrition, diabetes mellitus or liver disease). Despite of 
the fact that this combination of investigations might be considered as unusual and not 
generally accepted in the diagnosis of GH deficiency, we feel confident thatthese tests 
were sufficient to support this diagnosis, both against the background of the 
simultaneous presence of insufticiency of other anterior pituitary functions in virtually 
all patients, as well as on the basis of the previous demonstration of GH deficiency 
with classical stimulation tests in 4 patients. 
The administration of GH to adults with GH deficiency has been reported to lead to an 
increase in thigh muscle volume (39) and in FFM (18,40), while after cessation of GH 
treatment a decrease in thigh muscle volume was observed (41). 
To our knowledge no study has been reported comparing body composition in GH 
deficient adults with a matched control population. Since body composition is 
influenced by age and sex it is a prerequisite to have a control group matched for 
these variables, before differences in body composition can be attributed to other 
variables, such as GH deficiency. Since we have such a control group, we do present 
our data here, despite the disadvantage that the validation of the BIA equation in our 
groups had been performed with different techniques, underwater weighing in the 
controls and deuterium-oxide dilution in the patients. 
Table 2 shows that controls and patients in this study were identical for age, sex, 
height and weight, while Tables 3 and 4 demonstrate significant differences in body 
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composition: a significant higher FM and percent body fat, while FFM tended to be 
lower (not reaching significance) in the GH deficient patients. 
As is shown in Table 5 in the controls the impedance formula's of Lukaski et al (23) 
and Deurenberg et al (26) overestimate the FFM as measured by underwater 
weighing. This can be explained by the fact that the controls are older compared to 
the populations from which both formula's are derived. In older subjects FFM is 
generally overestimated when prediction formulas derived in younger reference 
populations are used, due to an altered body water distribution (42,43). 
The fact that in the patient population the impedance formulas did not overestimate 
the FFM found by o20-dilution, as a reference method, can be explained by the fact 
that in GH deficient patients the relative amount of intracellular water is increased (34), 
thus counteracting the lowering effect of age. 
The relation between impedance and FFM as depicted in Fig 2 shows a different 
regression line between H2 /R and FFM in the patient and controls, implying that a GH 
deficient patient has a higher impedance compared with a control alter adjusting lor 
differences in FFM and height. Since it has been demonstrated that the impedance is 
dependent on the intra cellular water {ICW) and extra cellular water (ECW) distribution 
(42), the increased impedance in GH deficiency can be attributed to a relative 
decrease in ECW. Indeed Novak et al (34) found a decrease in ECW as a percentage 
of body weight alter cessation of GH treatment in GH deficient children. In acromegaly 
ECW is increased (44), while alter successful treatment of acromegaly ECW decreases 
(45). During GH treatment of non-GH deficient adults acute fluid retention is observed 
(46,47). 
Unfortunately we were not in a position to use the same reference technique for body 
composition measurements in both patients and controls. It could be argued that the 
differences in the relation between FFM and body impedance, as given in figure 2, 
might be due to an invalid assumption of the constant mean hydration factor of 0. 73 
in the FFM in the GH-deficient patients. However to overcome the difference in 
intercept between the two regression equations, a mean hydration factor as low as 
0.68 would have to be used for the calculation of the FFM from TBW in the patient 
group. This value seems unreasonable low. The difference between the two prediction 
formulas for FFM from bioelectrical impedance for the patient and the control group 
(Rgure 2) indicates that FFM tends to be underestimated by BIA in GH-deficient 
patients. Yet, using either one prediction equations would be suitable to follow-up 
changes in body composition in untreated GH deficient people. However, the 
prediction equation used in our patients when employed to evaluate possible changes 
in body composition of GH-deficient patients before and during GH treatment, could 
result in an overestimation of the increase in FFM. Therefore impedance data in the 
evaluation of therapeutic effects of GH in GH-deficient patients have to be used 
carefully. 
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Jn conclusion GH-deficient subjects have higher FM and lower FFM compared to age, 
sex, height and weight matched controls. Body impedance values in GH deficient 
subjects are higher, compared to controls, even after correction for FFM and height, 
probably due to an altered body water distribution. This implies that prediction 
formulas for body composition from body impedance derived in normal healthy 
subjects will underestimate FFM in GH deficient subjects. 
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SUMMARY 
The effect of growth hormone administration to adult patients with growth hormone 
deficiency was studied on bone, protein, carbohydrate and lipid homeostasis as well 
as on body composition. 
Growth hormone was administrated at a dose of 25 ugjkgjday with a maximum of 
1.48 mg (4 IU) a day, for 6 months in 8 adults. Studies were done before the start and 
at 1, 3 and 6 months during therapy, as well as 3 months alter treatment had been 
stopped. 
Subjective well being as assessed by a short psychological test showed an 
improvement in 6 and no change in 2 patients. Body composition, as assessed by 
body impedance assessment and D,O dilution both showed an increase in lean body 
mass of 4 kg (5% of body weight), accompanied by a decrease in mean fat mass of 
3 kg. Nitrogen turnover studies showed a transient increase in fed state nitrogen 
balance due to an increase in the rate of protein synthesis, which exceeded a smaller 
increase in the protein degradation rate. 
Growth hormone treatment did not affect the circulating levels of 25(0H)-vit D, and 
PTH 1-84, while 1 ,25(0H),-vit D had significantly increased alter 6 months as well as 
3 months alter GH treatment ended. Osteocalcin and procollagen I levels as well as 
24 h urinary excretion of OH-proline and calcium rose during, but subsequently 
decreased rapidly alter GH administration had been stopped, while the increase in 
alkaline phosphatase persisted. This increase in markers of both bone resorption and 
bone formation indicate an activation of bone remodelling, but this was not reflected 
by an increase in bone density. 
Glucose levels measured before and during a normal breakfast increased during GH 
treatment, but serum insulin levels did not. Total cholesterol levels decreased by 0.5 
mmoljl. Levels of T4 and free T4 as well as rT3 decreased, while T3 increased during 
GH treatment. 
Therapy with growth hormone for 6 months in a dose varying between 6 to 25 
ugjkg/d increased lean body mass and decreased fat mass. The sense of general 
well-being improved in most patients. Furthermore GH therapy increased bone 
turnover without a measurable increase in bone density, caused some minor changes 
in lipid and carbohydrate metabolism, and increased the breakdown of thyroxine to T3. 
INTRODUCTION 
Growth hormone (GH) deficient adults are currently not substituted with GH. 
Spontaneous and stimulated GH secretion continues into normal adult life, however, 
although it decreases over time in later age (1-3). Recent reports by Salomon et al (4) 
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and Jorgensen et al (5) have demonstrated that GH treatment in GH deficient adults 
causes effects on body composition and exercise capacity which are of potentially 
clinical importance. We report the results of GH treatment lor 6 months ol8 long-term 
GH-deficient adults, as well as the changes 3 months alter the end of GH substitution 
on subjective well being, body composition and bone, carbohydrate and lipid 
homeostasis. 
PATIENTS AND METHODS 
Patients 
Eight adults with hypopituitarism (congenital or alter surgery for craniopharyngioma) 
or isolated GH deficiency were studied (Table 1). In all patients the initial diagnosis of 
hypopituitarism or isolated GH deficiency had been made at least 10 years before the 
present study. The patients had not received (pituitary-derived) GH for the past 10 
years. If present, other hormonal insufficiencies had been adequately substituted for 
at least one year before the start of the study. Before entering the study the presence 
of GH deficiency was confirmed by the combination of a plasma IGF-IIevel of 0.3 U jml 
or less (normal ranges: 0.34-1.90 Ujml in men and 0.45-2.20 U/ml in women), and a 
peak GH level of less than 10 mU /1 alter 1 ugjkg GHRH iv. None of the patients 
suffered from kidney or liver disease, diabetes mellitus or had a history of a 
malignancy. One patient (nr 5) had osteogenesis imperfecta. 
Alter aims and methods of the study were explained both orally and in writing, written 
informed consent was obtained from each patient before the start of the study, which 
was approved by the Ethics Committee of the University Hospital Dijkzigt. 
Methods 
All individuals were studied for a period of 9 months, during which the conventional 
hormone substitution regimen was not changed. They received GH during the first 6 
months only. 
All patients were asked not to change their diet and level of physical activity. Alter 
intensive instruction GH (Humatrope; supplied by Eli Lilly & Co, Indianapolis, lnd) was 
injected by the patients themselves scat bedtime, in a dose of 25 ugjkgjday, with a 
maximum of 1.48 mg (41U). Immediately before, 1, 3 and 6 months alter the start as 
well as 3 months alter the end of the 6 months of GH administration all patients were 
admitted to the clinical research unit for the following studies: 
a. Clinical chemical investigations, including haematology and assessment of kidney 
function, electrolytes, liver enzymes, 25(0H)-vit D, 1 ,25(0H),-vit D, PTH 1-84, 
osteocalcin, procollagen I, total T4, free T4, T3 and rT3, testosterone or oestradiol and 
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Table 1: Some physical characteristics of the patients. 
PAT. AGE DIAGNOSIS AGE SEX 11EIGHT WEIGHT BMI TBW FFM RESIST PITUITARY INSUFF. PEAK GH IGF-1 
nr yr M/F m kg kg/m2 kg kg Ohm A G T ug/1 U/ml 
I 25 Cranio 16 M 1.86 83.8 24.2 45.3 61.9 552 + + + 2.8 0.3 
2 30 Cranio 19 F I. 54 62.0 26.1 24.3 33.2 700 + 2.9 0.3 
3 39 Chromof ad 30 M 1.80 87.7 27 .I 46.8 63.9 488 + + + 3.8 0.2 
4 23 Cranio 9 M I. 72 92.8 31.4 41.6 56.8 527 3.2 0.4 
5 25 ld GH Oef II F 1.44 56.0 27.0 22.3 30.5 610 3 .I 0.3 
6 30 Cranio 17 M 1.82 94.8 28.6 48.5 66.3 504 + + + 2.3 0.3 
7 54 Cranio 45 M I. 74 74.0 24.4 41.2 56.3 490 + + + 4.3 0.4 
8 46 Cranio 40 M 1.77 99.0 31.6 47.7 65.2 445 + + + 2.4 0.4 
9 31 Cranio 16 F 1.65 87.0 32.0 40.8 55.7 496 + + + 1.4 0. I 
10 19 Cranio 16 F 1.66 48.0 17.4 26.5 36.2 763 + + + 6.6 0.4 
II 45 Id hypopit 15 F 1.37 57.0 30.4 21.8 29.8 686 + + + 1.7 0.4 
12 23 Id hypopit 10 M 1.69 56.5 19.8 29.3 39.9 710 + + + 1.0 0.2 
13 34 Id hypopit 13 M I. 61 46.6 18.0 25.4 34.7 862 + + + 4.2 0.5 
Mean: 33 1.67 72.7 26.0 35.5 48.5 603 3.1 0.3 
SEM : 3 0.04 5.1 1.3 2.8 3.9 34 0.4 0.0 
Present age, diagnosis (Cranio= craniopharyngioma; Chromof ad= Chromophobe adenoma; Id GH def= Idiopathic GH deficiency; 
Id hypopit= Idiopathic panhypopituitarism); age at diagnosis; BMI= Body Mass Index (kg/m2); TBW= total body water; FFM= 
fat-free mass (kg); impedance (Ohm); Pituitary insufficiency causing secondary A: adrenal-, G: gonadal-, T: thyroid-
insufficiency; peak GH (ug/1, highest GH level after stimulation with I ug GHRH/kg BW); IGF-1 (U/ml, basal plasma 
insulin like growth factor-!). 
IGF-1 levels were performed. 24 Hour urine was collected for the measurements of 
creatinine, calcium and OH-proline. These determinations were carried out with 
commercially available RIA or IRMA kits. All assays used had an intra-assay variation 
of less than 8% and an inter-assay variation of less than 12%, except for the inter-
assay variation of the 1 ,25(0H)2-vit D assay which amounted to 19.8%. 
b. After an overnight last basal cholesterol, HDL-cholesterol and triglycerides (TG) 
were determined as well as lipoprotein lipase (LPL) and hepatic triglyceride lipase 
activity (HTL) 20 minutes after the injection of 50 U heparin/kg BW as described 
previously (6). 
c. After another overnight fast blood glucose and plasma insulin levels were measured 
before and 30, 60 ,90, 120, 150 and 180 min after a standard breakfast. In the results 
section the sum of these 7 values has been reported. 
d. Subjective well being was assessed using a short (self-rating) questionnaire where 
the patients had to answer 10 questions using a 7 point scale. The questions regarded 
fatigue, physical and psychological fitness, activity and the ability to concentrate. The 
score ranges from 10 (no fatigue) to 70 (maximal fatigue). 
e. Body composition was determined by body impedance analysis (BIA) (model BIA 
101, RJL Systems Detroit Ml). Total body water (TBW), lean body mass (LBM) and fat 
mass were calculated from the measured impedance and reactance (7-10) by a RJL 
Systems supplied computer programme. 
In addition body composition was measured with the use of a multiple isotope dilution 
technique using op (11,12) and "'Na (13). After an overnight fast and insertion of a 
catheter into an antecubital vein blood was sampled and the patient was given, by 
mouth, a dose of 0.24 g 99.7 % D,O /kg body weight diluted in 200 ml H20 and an iv 
injection of 8 uCi of "'NaCI. After 150, 180 and 210 min 10 ml heparinised blood was 
withdrawn, and the plasma stored at -20 C until analysis. After sublimation, D,O 
concentration was measured by infrared spectrophotometry and TBW was calculated 
(11,12). LBM was calculated with the equation LBM;TBW/0.73 (14). Extra-cellular 
water (ECW) (and intra-cellular water, !CW) were calculated from the level of "'Na 
activity in blood drawn after 60, 70, 80 and 90 min, as described previously (13). 
f. Protein turnover was studied with a two-compartment model(15) using a single oral 
dose of 200 mg of ["N]glycine 99% (KOR Chemical, Boston, USA) (16) as the isotope 
to label the amino acid pool while urinary nitrogen (N) excretion products (urea and 
ammonia) were used to measure the nitrogen flux (17). During the study the patients 
were in a steady metabolic state, and received a liquid formula diet containing 1 g of 
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natural protein and 25 kcaljkg BW/d, divided into 11 identical hourly portions. The 
steady state was assumed to be reached 2 h after the first liquid meal, with a 
subsequent ccllection period of 9 h {17). The results are expressed as mg of N/9 h. 
g. Bone mineral density was determined every 3 months using both single photon 
absorptiometry {SPA) at the forearm (proximal and distal sites) and dual photon 
absorptiometry {DPA) of the second to fourth lumbar vertebrae. For the SPA 
measurements the method described by Nilas et al (18) with a Nuclear Data 1100a 
bone density scanner was used, the DPA measurements were done with a Novo BMC-
Iab 22a scanning device as described by Krollner and Nielsen (19). 
RESULTS 
In 3 patients {nos 1, 3 and 7) the initial dose of GH {25 ugfkg/d) had to be reduced 
within two weeks because of marked fluid retention of 3-5 kg and complaints related 
to carpal tunnel nerve pressure (which was confirmed with electromyography) in one 
of these patients (no 3). The actual dosages of GH used during the study period are 
listed in Table 1. 
Except lor patient no 2, all patients reported a considerable improvement in well being, 
endurance and physical fitness. This subjective information was reinforced by the 
Ondividual and) group mean results of the psychological testing (Fig 1), which shows 
a gradual reduction in fatigue and virtually no fatigue after 6 months of GH treatment. 
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Figure 1: Sell assessment score regarding fatigue {1 0: no fatigue; 70 maximal fatigue). 
The horizontal bar denotes the GH treatment period. * p < 0.05 vs 0 and 9 months. 
Mean .±. SEM, N ;8. 
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Figure. 2: Body composition parameters. a: body weight, b: body impedance; c,d: lean 
body mass and fat mass calculated from impedance; e,f lean body mass and fat mass 
determined by 0,0 dilution. * p < 0.01 vs 0 and 9 months, ** p < 0.01 vs 0 and P < 0.05 
vs >3 months, **p<0.05 vs baseline. Mean.±. SEM, N=S. 
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The effects of GH administration on body composition are depicted in Fig 2. Body 
weight (BW) did not change significantly (Fig 2a). Body composition as assessed by 
body impedance measurement showed significant changes: body impedance 
decreased sharply (Fig 2b), representing an increase in LBM ranging from 3.6-4.6 kg 
(Fig 2c). In parallel fat mass (FM) decreased by 2.4-3.0 kg (Fig 2d). The maximal 
change in LBM and fat mass had occurred already 1 month after the start of GH 
therapy. Three months after GH substitution ended, body composition was unchanged 
compared to baseline. Body composition as studied by 0,0 dilution showed similar 
changes in LBM and FM (Fig 2e and f). The results from the "Na dilution showed that 
the changes in TBW were due to changes in ECW, while ICW did not change (data 
not shown). 
The resu~s of the "N-glycine studies (Fig 3a-c) showed an initial increase in rates of 
protein synthesis one month after the start of GH administration while this effect seem 
to level off thereafter. Indeed nitrogen balance became significantly positive (p=0.02; 
two-tailed paired Student's t-test) after one month, mainly as a consequence of 
increased synthesis (p=0.05), while nitrogen degradation had non-significantly 
increased. II these parameters were expressed per kg LBM, however, no significant 
changes were observed (data not shown). 
Low pre-treatment serum IGF-1 levels increased to normal during GH substitution and 
returned to baseline 3 months after GH administration was stopped (Fig 4a). During 
GH treatment IGF-1 values ranged from 0.4 to 3.8 U /mi. Values above normal were 
noted in patients 6 (at 1,3 and 6 months) and 7 (at 1 and 3 months). Serum 
phosphorus levels showed similar changes (Fig 4b). The maximal renal tubular 
reabsorption of phosphorus corrected for the glomerular filtration rate (TmP /GFR) 
increased from 0.98 :!: 0.05, before GH treatment started, to 1.57 :!: 0.10 (p < 0.01) 
after one month of GH treatment. Three months after GH treatment ended TmP jGFR 
had decreased to 1.05 :!: 0.05. 
Serum calcium levels tended to increase after 1 month of GH treatment (Fig 5a), but 
the change did not reach statistical significance and thereafter calcium levels returned 
to pretreatment levels. Levels of (25)0H-vit D and PTH 1-84 did not change during the 
study period. The 1 ,25(0H),-vit D values amounted to 83.0 :!: 8.0 pmol/1 before the 
start ofGH therapy and had increased to 118.2:!: 15.8 pmoljl at six months (p<0.05), 
while they had increased further to 136.4 :!: 11.1 pmoljl three months after stopping 
GH administration (p <0.01 vs pretreatment and p <0.05 vs after 6 months of therapy). 
Alkaline phosphatase levels increased slowly during GH therapy and had not yet 
returned to baseline 3 months after treatment ended (Fig 5b). Mean circulating 
osteocalcin and procollagen I levels increased sharply compared with baseline during 
the 6 months GH treatment period (Fig 5c and d). Hydroxyproline excretion, measured 
in 24 h urine collections, increased and had returned to baseline 3 months after ending 
GH administration (Fig 5e). Calcium excretion in 24 h urine increased similarly, though 
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Figure 3: Nitrogen (N) turnover studies. a:protein synthesis, b:degradation and 
c:balance. Results expressed as gram N/ 9 hr (the length of the nitrogen turnover 
study period). * p=0.05 vs 0 and ** p =0.02 vs 0 by a paired two-tailed Student t test. 
Mean.± SEM, N=8. 
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Figure 4: Serum IGF-1 (a) and phosphorus (b) levels. 
* p<0.01 vs 0 and 9 months. Mean.±. SEM, N=S. 
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Figure 5: Parameters of bone metabolism.* p<0.05 vs 0 and 9 months,** p<0.01 
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Figure 6: Sum of 7 bloodglucose (a) and 7 serum insulin (b) levels measured before 
and after a normal breakfast.* p<0.05 vs 1 month. Mean±. SEM, N=B. 
122 
only statistically significant at 1 month (Fig 51). Pretreatment bone densities were 
lowered in the 5 female patients as compared with age-matched controls (20). The 
results of the DPA of the spine after 3 and 6 months of GH treatment showed a small 
but statistically significant decrease in bone density in comparison with pretreatment 
values (from 0.81 ;: 0.05to 0.79 :t 0.05 g hydroxyapatitejcm', p<0.05). Three months 
after GH treatment had been stopped DPA remained unchanged compared to 
pretreatment (0.81 ;: 0.05). SPA measurements showed no changes during the 9 
month study period. 
The sum of the 7 blood glucose levels measured before and after breakfast increased 
during GH administration (Fig Sa), while an increase in the sum of the 7 insulin levels 
did not reach statistical significance (Fig 6b). Glucose levels remained signmcantly 
elevated 3 months after stopping GH administration. The mean fasting and 2 h 
postprandial glucose levels maximally increased after 3 months from 3.8 ;: 0.2 and 4.2 
;: 0.3 to 4.3 :t 0.2 and 5.8 :t 0.4 mmoJjl, respectively (p<0.05 in both instances). The 
highest individual glucose levels measured at any time during the study amounted to 
9.0 and 8.1 mmolfl. 
The mean plasma cholesterol level (pretreatment 4.75;: 0.34) decreased after 1 (4.21 
;: 0.22) and 6 months (4.11 ;: 0.19) of GH treatment (p<0.05 in both instances). This 
decrease was due to a 10% decrease in plasma LDL-cholesterol. The suppressive 
effect of GH on total cholesterol was only seen in the 6 patients with a baseline 
cholesterol level above 4 mmol/1 (fig 7). In those 6 patients the change in circulating 
cholesterol concentrations during GH treatment was negatively correlated with the 
change in IGF-1 levels, at 6 months (p<0.05). Small changes in LPL activity and TG 
levels did not reach significance, nor were changes observed in HDL-cholesterollevels 
and HTL activity (data not shown). 
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Figure 7: Individual cholesterol levels in the 8 patients. - - - patients with a baseline 
serum cholesterol of <4.0 mmol, -- patients with a baseline cholesterol of >4.0 
mmoljl. 
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As is depicted in Fig Sa-d levels of T3 increased during GH treatment, in parallel with 
a simultaneous decrease of reversed T3 levels. Total and free T4 tended to decrease 
during GH treatment. Three months after stopping GH therapy all thyroid hormone 
parameters had returned to baseline. These changes were noted both in the 5 patients 
who received thyroxine substitution as well as in the 3 patients with isolated GH 
deficiency. 
DISCUSSION 
GH deficient adults have lower scores on quality of life assessment compared with 
healthy adults, while this improves during GH substitution (21 ). Another report 
suggested a beneficial effect of GH treatment of GH deficient adults with regard to their 
cognitive functions (22). Our study lacks a placebo-controlled period. Therefore the 
marked subjective improvement in well being during GH treatment in nearly all patients, 
which was corroborated by the changes in the score of the psychological test, can 
only be interpreted with great caution. We want to stress especially that we do not yet 
have a definitive validation of the quality of life questionnaire used (van Duivenvoorden 
et al, in preparation). However, 7 of the 8 patients reported that, if given the 
opportunity, they would resumed GH injections because of the increase they had felt 
in daily energy and initiative. 
The side effects of transient water retention which occurred in most of our patients, 
have been noted previously by others using comparable dosages of GH (4,5). These 
side effects were such that they forced us to reduce the GH dosage in 3 patients. 
Since the administered GH dose varied from 6 to 25 ug GH/kg BW no conclusion can 
be drawn from our study concerning an optimal GH dosage in GH-deficient adults. 
The changes we observed in body composition during GH therapy need some 
comments. The observed increases in lean body mass (amounting to as much as 5% 
of total body weight) together with simultaneous decreases in fat mass of 2.4-3.0 kg 
are in agreement with earlier studies (4,5,23,24). Also the reversal of these changes 
after cessation of treatment was to be expected (25). However, it is not directly 
understandable why the maximal change in body composition was already observed 
1 month after the start of GH treatment. The more positive nitrogen "balance" at 1 
month of GH therapy, with the subsequent decline to baseline levels hereafter, 
supports our observation that the increase in LBM occurred during the first month of 
GH therapy. Another explanation might be that the initial rise in LBM at 1 month was 
at least partially due to an increase in ECW (edema), followed by an increase in ICW 
(cell mass) together with a simultaneous decrease in ECW. However, our results using 
"Na to measure ECW and calculate ICW do not support this. 
No nitrogen turnover studies in GH deficient patients receiving GH have been reported 
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Figure 8: Thyroid hormone parameters: (a) Triiodothyronine (T3), (b) reversed T3, (c) 
total thyroxine (TT4) and (d) free T4 (FT4). * p<0.05 vs 0 and 9 months, ** p<0.05 
vs baseline,*** p<0.05 vs 1,3 and 6 months. Mean.±. SEM, N~8. 
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previously, to our knowledge. In postoperative patients receiving various nutritional 
regimens, short term \1 days) GH administration increased nitrogen turnover and 
synthesis while degradation either increased or remained unchanged (26-28). In obese 
patients, receiving hypocaloric nutrition, the nitrogen retaining effect of GH appeared 
to wear off after 3 to 5 weeks (29,30). 
As expected a marked increase in IGF-1 occurred during the 6 months of GH 
supplementation. The fact that supranormal circulating IGF-1 levels were observed in 
two patients questions whether we have used a "physiological" substitution dose of GH 
throughout the study in all patients. Phosphorus levels increased in parallel with the 
increase in IGF-1. Recent studies (31 ,32) suggest that IGF-1 and phosphorus 
metabolism are closely related, possibly via a direct effect ol IGF-1 on renal 
phosphorus handling (TmP jGFR). Indeed an increase in TmP /GFR was observed 
during GH administration in our patients. 
Longterm GH therapy in GH deficient children did not cause changes in 25(0H)-vit D 
andjor PTH levels, while the effects on circulating 1,25 (OH),-vit D concentrations were 
contradictory (33-35). The late increase of 1,25 (OH),-vit D during GH treatment might 
be the result of opposing effects ol GH/IGF-1 and increased phosphorus levels on the 
renal1-C< hydroxylase activity. During the follow-up period, however, phosphorus levels 
rapidly declined, whereas presumably renal cell mass remained at least initially 
increased. We want to hypothesize that this resulted in a net stimulation ol 1-<X 
hydroxylase activity and consequently in the late elevation of 1 ,25 (OH),-vit D levels. 
Previous reports, confirmed by our results, show that GH treatment induces a rise in 
markers of bone formation like osteocalcin (36,37), type I procollagen (38,39) and 
alkaline phosphatase. In addition a marked increase in OH-proline excretion (40), 
caused by an increase in degradation of both bone and non-bone collagen (41), 
indicates a higher rate of bone resorption. This increase in markers of bone resorption 
and formation indicates that GH induces activation of bone remodelling. As could be 
expected the higher bone turnover, initiated by a higher bone resorption, results in an 
initial loss of axial bone mass. However, after treatment with GH has been ceased 
bone mass returns to its initial level, illustrating that new bone remodelling units, once 
initiated by GH, completed a full life cycle and thereby demonstrating normal coupling 
between bone resorption and formation. 
As expected (42) an increase in blood glucose and insulin levels was observed after 
a normal breakfast during GH therapy. The significant negative correlation between the 
changes in cholesterol and IGF-1 levels, as observed in the 6 patients with a baseline 
cholesterol level above 4 mmoljl, are in accordance with the slight decrease in 
cholesterol levels during GH therapy of GH-deficient adults as observed by other 
investigators (4,43,44), and supports the hypothesis that GH activity infiuences 
cholesterol levels (6,45). As in our study, TG levels are usually normal in GH deficiency 
(43,44), while they do not change during GH treatment (4,46). 
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The observed changes in thyroid hormone parameters during GH treatment are 
consistent with the observations in healthy adults given 125 ug GH/kgjday for four 
days (47) and in a GH treatment study in GH deficient adults given 2 U GH/m' for 4 
months (4,48). They indicate a GH-induced increase in peripheral deiodination of T4 
to T3. The increase in T3 levels might contribute to the observed changes in body 
composition and the decrease in fatigue. In normals fasting induces an increase in GH 
(49) and a decrease in IGF-llevels (50,51), while T3levels decrease due to a reduction 
in peripheral conversion of T4 to T3 (54). Refeeding induces an increase in IGF-1 (51-
53) as well as an increase in T3 levels and a decrease in rT3 production (54). 
Therefore IGF-1 and not GH itself might stimulate the peripheral conversion ofT4 to T3 
during GH treatment of GH deficient adults. 
In conclusion, we think that based on the studies both in the literature and the study 
presented here GH suppletion in adults with GH deficiency is of value, both because 
of the subjective beneficial response reported by the patients, as well as because of 
some of the physical and biochemical changes observed in these patients. However, 
it is at present not clear which initial dose should be chosen and whether this dose 
might have to be increased after a certain 'wash-in' period in order to expand the 
improvements observed. 
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CHAPTER 6 
DISCUSSION OF THE MAJOR CONCLUSIONS 
The observation (chapter 2) that in elderly catabolic adults the effects of a GH dose 
of 25 ugjkg/d on nitrogen retention is comparable to that of 50 and better than that 
of 12.5 ugjkg/d, while side effects in these short term studies were less with the 25 
ug than with the 50 ugjkg/d dose, awaits confirmation by others. Recently a study 
was published in which elderly malnourished adults were treated for 21 days with 100 
ug GH/kgjd in addition to a diet aimed at maintaining body weight (1). Basal glucose 
levels reportedly did not increase. However, no non-fasting glucose levels or insulin 
levels were studied. A weight gain of 2.3 kg was partially ascribed to a gain in muscle 
mass solely on anthropometric measurements and the observation of increased 
urinary nitrogen retention. No nitrogen andjor sodium balances were performed in this 
last study. 
Before the routine use of GH in catabolic disease can be justified as an adjunct to 
nutritional treatment (either enteral or parenteral), larger studies of longer duration are 
needed demonstrating reduced morbidity andjor mortality and preferably accelerated 
recuperation. It is likely that the degree of catabolism, as well as the age of the patient 
are of influence on the effect of a standard GH dose. Therefore it might well be that 
while some malnourished/catabolic individuals optimally benefit from 25 ug GH/kgjd, 
others need a higher dose in order to achieve a maximal anabolic effect. The question 
of which dosage is optimal regarding desired and undesired effects is not only of 
medical interest but also a financial question, as presently 1.5 mg of GH (the daily 
dose of 25 ugjkg/d for a person of 60 kg) costs about 150,- DFI. 
Our results in rats (chapter 3) show no GH-induced stimulation of tumor growth, while 
cancer induced cachexia could be prevented. In humans, however, the potential 
beneficial effects of GH administration on tumor cachexia will be difficult to investigate, 
as the theoretical mitogenic and tumor growth-stimulatory effects of GH are at present 
difficult to refute. Few medical ethical committees will therefore approve GH trials in 
cachectic cancer patients. The use of GH for several weeks during a catabolic phase 
after trauma or severe disease is probably too short to induce tumors, while long-term 
GH replacement in GH deficient adults should pose no increased risk, provided the GH 
substitution doses are 'physiological'. However, in this regard the long-term use of 
pharmacological amounts of GH in healthy elderly people to reverse andjor prevent 
the consequences of normal aging (2), the use of GH in short but not GH-deficient 
children (3) and the long-term abuse of even higher amounts of GH as an anabolic 
agent in sports (4), should also looked at from the perspective of the potential 
mitogenic and tumor-growth promoting effects of the hormone. 
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Body composition assessment in GH deficient adults (chapter 4) showed decreased 
fat free mass and increased fat mass when compared with healthy age, sex, length 
and weight matched control subjects. In addition, in GH deficient subjects an altered 
distribution of intra- and extra-cellular water was found, which might limit the use of 
impedance measurements to assess changes in body composition in GH deficiency. 
However, the effects of GH substitution in GH deficient adults on body composition as 
measured by deuterium dilution were similar to the changes observed with impedance 
measurements (chapter 5). Body composition changed towards normal: fat mass 
decreased and fat-free mass increased. These observations and the report by 
Jorgensen et al that exercise capacity increased during GH replacement therapy (5), 
might explain the impressive improvement in subjective well being reported by virtually 
all patients. The effects of GH substitution on bone parameters demonstrated both 
increased bone formation and degradation. No increase in bone density was observed 
after 6 months of GH administration, despite the fact that bone densities in these 
patients at baseline was decreased when compared with controls. The GH-induced 
activation of bone remodelling might be of possible use in a combined treatment 
regimen for osteoporosis: while GH stimulates bone formation, bone degradation can 
be simultaneously reduced by biphosphanates. This combined approach might 
therefore lead to a net increase in bone density. 
The increased peripheral conversion of T4 to T3 possibly contributes to some of the 
effects of GH replacement (for example the changes in body composition and the 
decrease in fatigue). No conclusion can be drawn from our study, nor from the other 
studies published so far (5,6) regarding an optimal GH replacement dose. Perhaps 
an initially low GH dose should be gradually increased towards an individual optimum, 
which could be found on the basis of the subjective reactions by the patient, as well 
as the course of the circulating IGF-1 levels. Aside from the GH dose, other factors, like 
frequency, route and time of the administration also influence the results of GH 
replacement therapy (7). 
At present, it can be concluded that GH treatment of catabolic adult patients is still in 
the research phase as to whether it indeed achieves clinically important effects, and 
if this is proven, at what optimal dose. However, GH replacement therapy in GH 
deficient adults has been shown to be of considerable benefit, both objectively and 
subjectively. It is recommended therefore, that the use of GH replacement in this kind 
of patients will be accepted by the authorities in the Netherlands shortly. 
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SUMMARY 
The development of recombinant DNA technology has expanded the amount of human 
GH available for clinical use. GH treatment regimens in GH deficient children have 
been improved, cq dosages have been increased to maximize growth and treatment 
is now without the risk of transferral of viral infections. 
For the use of GH in adults questions have arisen like: in which clinical conditions, at 
what age and in which dose GH administration can be of possible benefit, and what 
are the possible (dose-related) side effects. The useful indications of GH treatment in 
adults can be divided in a) GH treatment, as an adjunct to the normal (nutritional) care 
of catabolic patients who, when healthy, secrete( d) normal amounts of GH and in b) 
GH replacement, in adult patients who secrete no or a lowered amount of GH. 
However, possible adverse effects of GH on sodium and fluid homeostasis, 
carbohydrate metabolism as well as possible mitogenic effects (chapter 1.5) raise 
questions concerning the safest (lowest) effective GH dose. 
As described in chapter 2, in elderly catabolic adults who consume an optimal enteral 
diet, a GH dose of 25 ugjkg/d for 4 days was shown to be equal to 50 and superior 
to 12.5 ugjkgjd in inducing nitrogen retention. The 25 ugjkg/d dose seemed to 
cause less -though not completely absent- side-effects: even at this dose (sodium and) 
fluid retention occurred. 
The use of GH in the treatment of cancer-induced cachexia seems troublesome at 
best, considering the possible mitogenic and tumor growth-stimulating effects of GH 
and IGF-1 (chapter 1.5). In chapter 3 it was shown, however, that in vivo in a rat model 
GH administration (in a pharmacological dose of 1 mgjratjday) was found to prevent 
cancer induced cachexia (and to increase lowered IGF-1 levels) without stimulating 
tumor growth, in spite of the observation that in vttro IGF-1 stimulated the growth of 
cultured tumor cells prepared from this transplantable rat pituitary tumor. 
As discussed in chapter 1.2 and 1.3 physiologic GH secretion continues well into old 
age and GH affects many tissues, either directly or indirectly through IGF-1. Therefore, 
adults with GH deficiency (either congenital or iatrogenic) might benefrt from GH 
replacement As demonstrated in chapter 4 GH deficient adults have an abnormal 
body composition when compared with age, height, weight and sex matched controls: 
they have more fat and less fat-free mass. In chapter 5 GH substitution treatment for 
6 months in 8 GH deficient adults had impressive effects on this abnormal body 
composition, as well as on bone, carbohydrate and protein metabolism. Body 
composition changed towards normal: fat mass decreased and fat free mass 
increased. In parallel a great improvement in subjective well-being was observed. 
Markers of bone resorption and bone formation increased both, indicating an increase 
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in bone remodelling. However, during this 6 month study period bone density had not 
increased under the influence of GH administration. Glucose levels increased slightly 
without increasing insulin levels. Nitrogen turnover studies showed a transient increase 
in nitrogen balance due to a slightly greater increase in protein synthesis than in 
protein degradation. Finally changes of thyroid hormone parameters indicated 
increased peripheral conversion of T4 to T3. The impressive subjective benefit of GH 
replacement in adults with GH deficiency warrants the consideration of accepting such 
therapy in the routine treatment of this type of patients. 
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SAMENVATTING 
De ontwikkeling van recombinant DNA technieken heeft geleid tot een toename van 
de voor de kliniek beschikbare hoeveelheid humaan GH. GH behandeling in GH 
deficiente kinderen is verbeterd cq de geadviseerde doseringen teneinde een 
maximale lengte te bereiken zijn gestegen en de behandeling is nu zonder het risico 
van de overdracht van virale infecties. 
Eventueel gebruik van GH bij volwassenen leidt tot vragen als: bij welke aandoeningen, 
op welke leeftijd en in welke doseringen kan GH behandeling wellicht nuttig zijn en wat 
zijn de mogelijke (dosis afhankelijke) bijwerkingen. De indicaties voor GH behandeling 
bij volwassenen zijn te verdelen in a) GH toediening naast de normale (voedings) 
behandeling van katabole patienten die, indien gezond normale GH productie hebben 
en in b) GH substitutie therapie bij volwassenen die geen of te weinig GH produceren. 
In verband met eventueel nadelige effecten van GH op natrium en vocht balans, 
koolhydraat stofwisseling en mogelijke mitogene effecten (hfdst 1.5) rijst de vraag wat 
de veiligste (laagste) effectieve GH doseringen zijn. 
In hfdst 2 wordt beschreven dat in oudere katabole volwassenen die een optimaal 
enteraal dieet gebruiken een GH dosis van 25 ugjkgfd gedurende 4 dagen net zo 
effectief als 50 en effectiever dan 12.5 ugfkg/d aanleiding geeft tot stikstof retentie. De 
25 ugjkg/d dosis leek minder doch niet geheel zonder bijwerkingen te zijn: ook deze 
dosis veroorzaakte (natrium en) vocht retentie. 
Het gebruik van GH bij de behandeling van cachexie veroorzaakt door maligniteiten 
is op zijn minst dubieus gezien de mogelijke mitogene en tumor groei bevorderende 
effecten van GH en IGF-1 (hfdst 1.5). In hfdst 3 wordt beschreven dat in vivo, in een 
ratten model, GH toediening 0n een farmacologische dosering van 1 mgfratjdag) 
cachexie voorkomt (en verlaagde IGF-1 spiegels deed stijgen) zonder tumor groei te 
stimuleren, ondanks het feit dat in vitro IGF-1 de tumorcel groei van deze ratten-
hypophyse tumor stimuleert. 
In hfdst 1.2 en 1.3 word! beschreven dat de fysiologische GH productie aanwezig blijft 
tot op hoge leeftijd en dat GH effecten heeft op vele weelsels, hetzij direct of indirect 
via IGF-1. Derhalve kunnen volwassenen met GH deficientie (hetzij aangeboren of 
verkregen op latere leeftijd) mogelijk baat hebben bij GH behandeling. In hfdst 4 wordt 
beschreven dat GH deficiente volwassenen een afwijkende lichaams samenstelling 
hebben. In vergelijking met leeftijd, lengte en gewicht gematchte controles hebben zij 
meer vet en minder vet-vrije massa. In hfdst 5 worden indrukwekkende effecten 
beschreven van GH substitutie gedurende 6 maanden bij 8 GH deficiente volwassenen 
op de abnormale lichaams samenstelling, alsmede op bot, koolhydraat en eiwit 
metabolisme. Lichaams samenstelling normaliseerde: vet massa nam af en vet vrije 
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massa nam toe. Tegelijkertijd trad er een forse verbetering op van het subjectief 
welbevinden. Zowel de parameters voor bot resorptie als voor bot vorming stegen ten 
teken van een toegenomen bot ombouw. Gedurende de 6 maanden durende GH 
behandeling trad er echter geen stijging van de bot densiteit op. Bloedsuiker spiegels 
stegen iets, zonder stijging van de insuline spiegels. Onderzoek van de stikstof 
turnover liet een tijdelijke stijging van de stikstof balans zien ten gevolge van een iets 
grotere toename van de eiwit synthase in vergelijking met de eiwit afbraak. Tenslotte 
toonden de veranderingen in schildklier hormoon parameters een toegenomen perifere 
conversie van T4 naar T3. De indrukwekkende subjectieve verbetering van GH 
toediening aan volwassenen met GH deficientie rechtvaardigt de overweging om deze 
behandeling bij deze patienten routinematig toe te gaan passen. 
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140 
STELLING EN 
behorend bij het proefschrift van A. Binnerts 
1. De minimale dosering GH nodig om de stikstof balans positief te beinvloeden 
bij oudere volwassenen tijdens optimale orale voeding bedraagt 25 
I'Q/kgBW /dag. 
2. In het ratten model van de transplanteerbare hypofysetumor 7315b voorkomt 
GH toediening het ontstaan van door kanker geinduceerde cachexie, zonder 
dat dit aanleiding geeft tot stimulatie van kankergroei. 
3. Groeihormoon deficientie op de volwassen leeftijd geeft aanleiding tot een 
afwijkende lichaamssamenstelling. 
4. Ook op de volwassen leeftijd dient GH deficientie behandeld te worden. 
5. De term "groeihormoon" dekt de lading niet, het zou beter zijn dit hormoon 
"anaboline" te noemen. 
6. Het nuttig effect van totale parenterale voeding is onbewezen. 
7. Niet enzymatische glycosylering van hemoglobine wordt mede beinvloed door 
factoren anders dan glucose, ca. zuurstof spanning en 2,3-diphosphoglyceraat 
gehalte. 
Smith RJ, Koenig RJ, Binnerts A, Soeldner JS, Aoki TT. J Clin Invest 
1982;69:1164-9. 
8. De verhoging van het risico op auto ongevallen bij diabetici is te gering om 
beperking van de afgifte van rijbewijzen te rechtvaardigen. 
Hansotia P, Broste SK. N Engl J Med 1991;324:22-6. 
9. Bij diabetici gaat de behandeling van hypertensie met diuretica gepaard met 
een viervoudige stijging van de sterfte. 
warram JH, Leffel LMB, Valsania P, Christlieb AR, Krolewski AS. Arch Intern 
Med 1991;151:1350-6. 
10. Wettelijke maatregelen dienen gene men te worden ter beteugeling der 
kwakzalverij. 
(stelling bij het proefschrft van A. Binnerts, Over lokalisatie van functies in het 
cerebellum; Amsterdam, 7 april 1908) 
11. Een algeheel verbod van het gebruik van saccharine in voedings- en 
genotmiddelen behoort u·,tslu·,tend afhankelijk gesteld te worden van de 
beantwoording van de vraag, of deze stof al dan niet schadelijk is veer de 
gezondheid. 
(stelling bij het proefschrift van A.J. Kluyver, Biochemische suikerbepalingen; 
Delft, 15 mei 1914) 
12. Het is van belang het huidige honoreringssysteem voor artsen bij te stellen, 
opdat het gebruik van technologie niet hager wordt beloond dan bijvoorbeeld 
het gesprek met een patient of het lichamelijk onderzoek. 
(Kiezen en delen, advies in hoofdzaken van de commissie "Keuzen in de zorg"). 
13. Het feit dat per geinstitutionaliseerd geestelijk gehandicapt kind veel meer 
gemeenschapsgeld wordt uitgegeven dan er beschikbaar is voor ouders die 
met hulp van derden hun geestelijk gehandicapt kind thuis willen opvoeden is 
strijdig met de geest van het beg rip "zorgzame samenleving". 
14. Het gebruik van groeihormoon in de veehouderij dient gestimuleerd te worden, 
onder andere omdat hierdoor het stikstof en fosfaat gehalte van de mest, en 
derhalve de verzuring, verminderd kan worden. 
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